

PATENT SPECIFICATION

(11) 1 516 458

1 516 458

- (21) Application No. 40664/76 (22) Filed 30 Sept. 1976
(31) Convention Application No. 727 365
(32) Filed 27 Sept. 1976 in
(33) United States of America (US)
(44) Complete Specification published 5 July 1978
(51) INT CL² C12K 1/02
(52) Index at acceptance C6F 1X 2X



(54) MODIFIED MICROORGANISMS AND METHOD OF PREPARING AND USING SAME

(71) We, RESEARCH CORPORATION, a corporation of the State of New York, of 405 Lexington Avenue, New York, New York, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to the development of microorganisms possessing special properties. More particularly, this invention is concerned with the genetic alteration of microorganisms, such as *Escherichia coli*, to impart special properties thereto, particularly genetically-linked properties. It is known to effect genetic changes in microorganisms by exposing microorganisms to radiation, such as ultraviolet radiation, x-ray radiation or by exposure to chemical mutagens. Many genetically-altered microorganisms produced by such techniques are of substantial value and utility, not only in commerce and medicine but also in research.

One area of research of special interest, not only because it might make available special microorganisms heretofore unknown which would be useful in medicine for the treatment of diseases, but also because such heretofore unknown microorganisms might present unique biohazards, involves recombinant DNA molecules. Techniques are known and have been developed for inserting recombinant DNA molecules, e.g. plasmid or viral cloning vector DNA containing DNA molecules from any organism or virus, into microorganisms such that these recombinant DNA molecules become part of the genetic structure or make-up of the microorganisms into which they have been inserted. The potential utility and hazards of such recombinant DNA molecular research have received wide publication.

It is an object of this invention to provide a microorganism useful in recombinant DNA research activities.

It is another object of this invention to provide techniques for altering the properties, particularly the genetic properties of microorganisms such as bacteria, yeast and the like.

How these and other objects are achieved will become apparent in the light of the disclosure. In at least one embodiment of the practice of this invention at least one of the foregoing objects will be achieved.

In accordance with one aspect of the invention, there is provided a microorganism having the following characteristics:

(a) said microorganism being capable of having recombinant DNA or other foreign genetic information introduced therein and recovered therefrom along with its expression with production of useful gene products;

(b) said microorganism being dependent for growth and survival upon defined conditions;

(c) said microorganism being incapable of establishment or growth or colonization and/or survival under conditions or in ecological niches that are non-permissive for said microorganism;

(d) said microorganism being capable of causing DNA or other foreign genetic information incorporated therein to undergo degradation under conditions or in ecological niches that are non-permissive for said microorganism;

(e) said microorganism being capable of permitting cloning vectors incorporated therein to be dependent for their replication, maintenance and/or function on said microorganism;

BEST AVAILABLE COPY

(f) said microorganism being substantially incapable of transmitting cloning vectors or recombinant DNA or other foreign genetic information incorporated therein to other organisms under non-permissive conditions for said microorganism;

(g) said microorganism being capable of being monitored by suitable means and/or techniques without substantial alteration of said microorganism; and

(h) said microorganism being susceptible of substantially minimal contamination with other organisms when recombinant DNA or other foreign genetic information is incorporated therein and being substantially incapable of contaminating other organisms when incorporated therein or consumed thereby when recombinant DNA or other foreign genetic information is present in said microorganism.

The invention also includes a method for transforming a microorganism as described above with plasmid vector DNA which includes the steps of subjecting the microorganism to a cold osmotic pressure shock treatment by suspension in a chilled salt solution, admixing the chilled microorganism with the DNA and subjecting the mixture to a hot shock treatment by rapidly raising the temperature to above ambient temperature.

The invention also includes a method in which recombinant DNA is introduced into a microorganism suitable for replication therein or for the production of material from said microorganism dependent on said recombinant DNA upon growth or culturing of said microorganism, wherein there is employed as said microorganism a microorganism as described above.

In developing or producing microorganisms as described hereinabove, deletion mutations and/or two mutations affecting the same function are desirably employed whenever possible to preclude or greatly diminish the probability or possibility that the strain can lose the property conferred by such mutation or mutations. Examples of such microorganisms are *Escherichia coli* K-12, 1776, *Escherichia coli* K-12, 1972, *Escherichia coli* K-12, 1976 and *Escherichia coli* K-12, 2076. Additionally, techniques have been developed and employed for imparting special properties, e.g. genetic properties, to microorganisms which render the resulting microorganism unique.

Also, techniques have been developed for the handling of plasmid cloning DNA vectors for eventual insertion into microorganisms for testing therein, such as the above-mentioned microorganisms, and techniques have been developed for the transformation of microorganisms, such as the above-identified microorganisms, for the introduction of recombinant DNA molecules therinto. Also techniques have been developed in connection with the development or production of the above-identified microorganisms which impart special genetically-linked properties thereto, which techniques are applicable to a large number and diversity of microorganisms, including not only bacteria but also yeast and other cellular material.

Although emphasis has been placed in the disclosure of this invention with respect to the usefulness of the special microorganisms of this invention in recombinant DNA research, special microorganisms prepared in accordance with the teachings of this invention would have wide ranging utility. For example, microorganisms, such as yeast cells, could be prepared having special properties which permit ready lysing or breakdown of the yeast cells, e.g. yeast cells having a substantially weakened wall structure. Bacterial microorganisms having weakened wall structures and/or other special physical properties are also capable of being prepared in accordance with this invention. Additionally, as indicated hereinabove with respect to *E. coli*, not only are the *E. coli* microorganisms of this invention useful in recombinant DNA research activities but also *E. coli* microorganisms which may be produced in accordance with the practice of this invention would be useful in sewage treatment plants or fermentation plants, such as fermentation plants based on *E. coli* for the fermentation of glucose to produce a mixture of commercially valuable organic acids. It is known that *E. coli* fermentation of glucose results in a mixture of organic acids, e.g. succinic acid, lactic acid, acetic acid and formic acid as well as other commercially useful products.

In the practices of this invention, particularly for the development of microorganisms having the properties indicated hereinabove, such as the production of the microorganism *E. coli* K-12, 1776, and for the production of other microorganisms, such as 1972, 1976 and 2076, all substantially possessing the desirable properties set forth hereinabove, for the production of other microorganisms, e.g. genetically altered microorganisms, certain techniques for

the induction, isolation and characterization of mutations have been developed. For example, Mutation Chart A enumerates and describes properties of mutations alone or in combination that have been shown to confer the desirable properties set forth hereinabove.

MUTATION CHART A.

The gene symbol designations are those used by Bachmann, et al. (Bacteriol. Rev. 40:116—167, 1976) for known genes and for unknown genes identified during development of this invention, follow the conventions of genetic nomenclature proposed by Demerec, et al. (Genetics 54:61—76, 1966).

- 10 a1. for efficient introduction into microorganisms of foreign genetic information: 10
 - (1) *hsdR* — abolishes restriction, used in *x*1776 and *x*2076.
 - (2) *hsdS* — abolishes restriction and modification, used in *x*1972, *x*1976 and other strains being developed and mentioned hereinabove.
 - (3) *dap* and/or *asd* — abolishes synthesis of diaminopimelic acid (see below) and increases transformability about 3 fold, used in *x*1776, *x*1972, *x*1976 and *x*2076. 15
 - (4) Δ [*gal-uvrB*] — eliminates galactose in lipopolysaccharide in outer membrane (i.e., outer layer of cell wall) and increases transformability 5 to 10 fold (this mutation has other attributes as mentioned below). (*galE* mutations accomplish the same objective but have not been used in any strains because of the added advantages of using the Δ [*gal-uvrB*] mutation with deletes the *galE* gene.) 20
Used in *x*1776, *x*1972, *x*1976 and *x*2076.
 - (5) *endA* — eliminates endonuclease I and increases transformability 5 to 10 fold, not used in *x*1776 but is used in *x*1972, *x*1976, *x*2076.
- 25 a2. for efficient recovery of foreign genetic information from microorganisms: 25
 - (1) *dap* and *asd* (see above) — cause cells to be fragile and facilitate their lysis to recover recombinant DNA, used in *x*1776 and *x*2076 and *dap* mutations alone in *x*1972 and *x*1976.
 - (2) *rfa* and *oms* — when together cause alteration in outer membrane structure causing cells to be more sensitive to lysozyme and detergents used during lysis of cells to recover recombinant DNA, used in *x*1776 and *x*2076. 30
 - (3) *rfa*, *lpcA* and *lpcB* — when alone or in combination cause alteration in lipopolysaccharide in outer membrane causing cells to be more sensitive to lysozyme and detergents used during lysis of cells to recover recombinant DNA, used in *x*1972, *x*1976, *x*2076.
- 35 a3. for expression of foreign genetic information with production of useful products: 35
 - (1) *minA* + *minB* — cause production of minicells that lack chromosomal DNA but can possess plasmid vector DNA and thus permit studies on the expression of foreign DNA, present in *x*1776 and *x*2076.
- 40 Manipulations necessary to achieve expression of foreign DNA in *E. coli* require development of specific plasmid or phage cloning vectors which in turn requires use of *in vitro* recombinant DNA molecule construction techniques. Other standard genetic manipulations will have to be done to the host, such as by introducing mutations that block the degradation of foreign proteins (i.e., *deg*, *lon*) and permit the "excretion" of foreign proteins outside the cell into the culture medium. 45
- b. for microorganisms to be solely dependent on uniquely defined conditions for their growth and survival:
 - (1) *dap* — abolishes synthesis of diaminopimelic acid, a unique essential ingredient of rigid layer of cell wall which is not found in nature, used in *x*1776, *x*1972, *x*1976 and *x*2076. 50
 - (2) *asd* (Δ [*bioH-asd*]) — also abolishes synthesis of diaminopimelic acid, used in *x*1776 and *x*2076.
 - (3) *thyA* — abolishes synthesis of thymidine-5'-monophosphate, an essential ingredient of DNA. Cells have to be supplied with either thymidine (which is probably not prevalent in nature) or thymine (which is more prevalent in nature), used in *x*1776, *x*1972, *x*1976 and *x*2076. 55
 - (4) *deoA* — abolishes ability of *thyA* strains to use low to moderate concentrations of thymine and makes them dependent on thymidine to satisfy requirements of *thyA* mutation, used in *x*1972, *x*1976 and *x*2076. 60

(5) *upp* — abolishes a minor pathway that permits *thyA deoA* strains to grow with high concentrations of thymine in the medium. Thus a strain with *thyA deoA* and *upp* mutations is completely dependent on thymidine in the growth medium and thus survives less well in nature than a strain with just the *thyA* mutation, used in $\times 1972$, $\times 1976$ and $\times 2076$.

c. to preclude establishment or growth or colonization and/or survival of microorganisms under conditions or in ecological niches that are considered to be natural or undesirable habitats of the microorganisms or their progenitors:

(1) *dap* and *asd* (see above) in conjunction with mutations such as $\Delta[gal-uvrB]$ (used in $\times 1776$, $\times 1972$, $\times 1976$ and $\times 2076$), *galE*, *galU*, *man* and *non* that abolish colanic acid synthesis precludes long-term survival by causing cell lysis in essentially all environments — natural and unnatural. The rate of death by lysis, however, is dependent on the ability of the environment to support metabolism of microorganisms.

(2) *thyA* (as used in $\times 1776$) plus *deoA* and *upp* (as used in $\times 1972$, $\times 1976$ and $\times 2076$) precludes long-term survival in essentially all environments — natural and unnatural. The rate of death, however, is dependent on the ability of the environment to support metabolism of microorganisms.

(3) *rfb* and *oms* (as used in $\times 1776$ and $\times 2076$) confer increased sensitivity to bile, thus preventing survival in the intestinal tract, confer increased sensitivity to detergents that are likely to be encountered in waste water collected by sewerage systems, and cause increased sensitivity to a diversity of drugs, antibiotics, and chemicals that are likely to be encountered in nature as pollutants in waste water collected by sewerage systems and in rivers, lakes, etc. These sensitivities are independent of metabolic activities of cells and should reduce survival in waste water, rivers, etc.

(4) *rfa*, *lpcA* and *lpcB* — whether alone or in combination confer same properties as *rfb* and *oms* mutations, used in $\times 1972$, $\times 1976$ and $\times 2076$.

(5) $\Delta[gal-uvrB]$ — causes microorganism to be inordinately sensitive to ultraviolet light (and thus sunlight), since cells cannot repair UV-induced damage either in dark or in presence of visible light. This property diminishes survival in air, on soil and plants and in surface waters exposed to sunlight and sensitivity is independent of metabolic activity of cells, used in $\times 1776$, $\times 1972$, $\times 1976$ and $\times 2076$.

(6) *recA* — causes microorganism to be inordinately sensitive to ultraviolet light and chemical mutagens and exposure to same leads to rapid death with concomitant destruction of genetic information, used in $\times 1976$. When used in conjunction with *polA*(CS) (see below) leads to death with concomitant destruction of genetic information at 32°C and below even in absence of ultraviolet light and/or chemical mutagens, used in $\times 1976$.

d. to cause genetic information contained in microorganisms to undergo degradation under conditions or in ecological niches that are considered to be natural and/or undesirable habitats of the microorganisms or their progenitors:

(1) *thyA* — abolishes synthesis of thymidine-5'-monophosphate which is needed for DNA synthesis and in absence of thymine or thymidine causes thymineless death which is associated with concomitant degradation of DNA, used in $\times 1776$.

(2) *thyA deoA upp* — cause obligate requirement for thymidine which is not prevalent in nature and thus result in more rapid and efficient degradation of genetic information than caused by *thyA* mutation alone, used in $\times 1972$, $\times 1976$ and $\times 2076$.

(3) *polA*(CS) — causes DNA polymerase I to be non-functional at temperatures of 32°C. and below (i.e., "cold" sensitive). DNA polymerase I is principally involved in repair of damage to DNA but also plays an important function during DNA synthesis. When the enzyme is non-functional, thymineless death and DNA degradation occur at accelerated rates. This is the first isolation of such cold-sensitive *polA* mutations, used in $\times 1972$ and $\times 1976$.

(4) *recA* — abolishes genetic recombination and causes cells to be inordinately sensitive to ultraviolet light (i.e., sunlight) and other chemicals that might be encountered in environment. Exposure to UV, etc., causes rapid degradation of DNA. In conjunction with *polA*(CS) causes rapid degradation of DNA at 32°C. and below, thus leading to rapid destruction of genetic information in microorganisms

that escape to all environments other than within a warm-blooded animal, used in $\times 1976$.

The constellation of mutations *thyA deoA upp polA(CS) recA* as used in $\times 1976$ gives a vast improvement in safety over that afforded by the *thyA* mutation alone as used in $\times 1776$.

e. to permit cloning vectors used for recombinant DNA molecule research to be dependent on microorganisms for replication, maintenance and/or function:

(1) *supE* — amber suppressor that rectifies amber nonsense mutations that might be present in viral or plasmid cloning vectors so that their maturation, maintenance, function and/or replication would be dependent on microbial host. It is believed that most microorganisms in nature do not possess amber suppressor mutations. Thus, viral or plasmid cloning vectors could not mature, function and/or replicate in these wild-type microorganisms that might be encountered in nature, used in $\times 1776$, $\times 1976$, and $\times 2076$.

(2) *supF (tyrT)* — another type of amber suppressor with similar function but different specificity than *supE* used in $\times 1976$.

(3) *sup+* — absence of any and all nonsense suppressor mutations. Permits use of viral vectors that possess amber mutations in genes specifying synthesis of viral structural proteins such as tail proteins so that only non-infectious viral heads containing recombinant DNA are produced. Also permits lysogenization of host with viral vectors possessing amber mutations so that virus maturation is not possible and viral vector maintenance is solely dependent on replication of host chromosome, used in $\times 1972$.

(4) *polA(CS)* — causes DNA polymerase I not to function at temperatures below 32°C. Certain plasmid cloning vectors, such as ColEI and its derivatives, are dependent on a functional DNA polymerase I for their vegetative replication. Thus, these plasmids cannot replicate in *polA(CS)* cells at 32°C. or below and are diluted out (i.e., lost) used in $\times 1972$ and $\times 1976$.

(5) *recA* — abolishes genetic recombination which is necessary for stable maintenance of λdv plasmid cloning vector, used in $\times 1976$.

f. to preclude or minimize or reduce potential or capability of microorganisms to transmit recombinant DNA to other organisms in nature:

All of the mutations cited above that reduce survival of the host microorganism and which lead to degradation of genetic information in other than carefully controlled "laboratory" environments will, of course, limit transmission of recombinant DNA to other organisms. However, some of these mutations as well as others have specific beneficial effects on reducing transmission of recombinant DNA that have not been mentioned above.

(1) *thyA* — since DNA synthesis is needed for virus cloning vector propagation and since DNA synthesis accompanies and is probably required for conjugational transmission of plasmid DNA, the *thyA* mutation (as used in $\times 1776$) along with the *deoA* and *upp* mutations (as used in $\times 1972$, $\times 1976$ and $\times 2076$) will block DNA synthesis in non-laboratory environments and thus inhibit recombinant DNA transmission.

(2) *polA(CS)* — functional DNA polymerase I is necessary for the conjugational transmission of the ColEI cloning vector and its derivatives. Thus, the presence of the *polA(CS)* mutation minimizes, if not precludes, transmission of recombinant DNA contained on ColEI vectors at 32°C. and below, used in $\times 1972$ and $\times 1976$.

(3) $\Delta[gal-uvrB]$ (used in $\times 1776$, $\times 1972$, $\times 1976$ and $\times 2076$), *lps* and *oms* (used in $\times 1776$ and $\times 2076$) and/or *rfa*, *lpcA* and/or *lpcB* (used in $\times 1972$, $\times 1976$ and $\times 2076$) — alter outer membrane of cell and reduce ability of cell to mate with a diversity of different types of donor strains and thus to inherit conjugative plasmids which are necessary for the mobilization and transmission of the non-conjugative (i.e., non-self-transmissible) plasmids used as cloning vectors. These mutations also confer resistance to phages D108 and Mu and partial or complete resistance to phage P1, which are generalized transducing phages, thus reducing the probability of transmission of recombinant DNA by transduction. The $\Delta[gal-uvrB]$ deletion mutation also eliminates the normal integration sites on the chromosome for the temperate transducing phages λ , 82 and 434.

(4) *tonA* — confers resistance to phage T1, T5 and $\phi 80$ and thus eliminates transductional transmission of recombinant DNA by the transducing phages T1 and $\phi 80$, used in $\times 1776$, $\times 1972$, $\times 1976$ and $\times 2076$.

(5) $\Delta[bioH-*asd*]$ — confers resistance to transducing phage λ , used in x_{1776} and x_{2076} .

(6) *sup*⁺ — absence of any and all nonsense suppressors which prevents production of infectious viral vectors containing recombinant DNA either when the viral vector contains amber nonsense mutations in genes specifying tail proteins or when a viral vector containing amber mutations in any gene specifying viral structural proteins is integrated into, and is therefore dependent upon replication of, host chromosome, used in x_{1972} .

g. and h. to permit monitoring of microorganisms and minimize likelihood of contamination of microorganisms during recombinant DNA molecule research:

(1) *nalA* — confers resistance to nalidixic acid. Since nalidixic acid resistance is rare in microorganisms encountered in nature and since the frequency of nalidixic acid resistance mutations is extremely low, the *nalA* marker can be used to monitor escape and survival of very low numbers of the host microorganism. Nalidixic acid can also be added to cultures during transformation with recombinant DNA to essentially preclude transformation of the contaminating microorganism, used in x_{1776} , x_{1972} , x_{1976} and x_{2076} .

(2) *cycA* and *cycB* — confer resistance to cycloserine which permits use of cycloserine in place of or in conjunction with nalidixic acid, used in x_{1776} and x_{2076} .

(3) *thyA* — confers resistance to trimethoprim which permits use of trimethoprim in place of or in conjunction with nalidixic acid and/or cycloserine, used in x_{1776} , x_{1972} , x_{1976} and x_{2076} .

MATERIALS AND METHODS USED IN GENETIC MODIFICATION OF MICROORGANISMS

General. All methods are known and are described by Miller (*Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory, 1972) or in the references cited unless otherwise indicated.

Media. Complex media included Penassay broth and agar (Difco; 8 g NaCl/l was added to Penassay agar unless otherwise indicated), L broth (Lennox, 1955), L agar (L broth containing 15 g agar/l except for use with P1L4 in which case 12 g agar/l and 2.5×10^{-3} M CaCl_2 were added), Brain Heart Infusion Broth and Agar (Difco, Trademark), Tryptone broth (10 g tryptone and 5 g (NaCl/l and agar (Tryptone broth containing 12 g agar/l), EMB agar (Difco EMB Agar Base containing 5 g yeast extract and 5 g NaCl/l and MacConkey Base Agar (Difco). EMB and MacConkey agars were supplemented with sterile carbon sources to desired concentrations (usually 1%) after autoclaving. L soft agar was L broth containing 6.5 g agar/l.

Synthetic media were ML and MA (Curtiss, 1965) and were supplemented with amino acids, purines, pyrimidines and vitamins at optimal concentrations (Curtiss et al., 1968) and carbon sources to 0.5%. Casamino acids (CAA; Difco) were added at 0.5 or 1.5% as indicated. Thymidine (Thd) or thymine (Thy) was added at 10 $\mu\text{g/ml}$ for complex media and at 40 $\mu\text{g/ml}$ for synthetic media. Biotin (Bio) was used at 0.5 $\mu\text{g/ml}$ and DL-diaminopimelic acid (DAP) at 100 $\mu\text{g/ml}$, the latter being added to all media and diluents for work with *dap* mutants. Purine, pyrimidine and vitamin supplements were added to Tryptone broth and agar and MacConkey agar when used for strains that required these compounds.

Buffered saline with gelatin (BSG; Curtiss, 1965) was used as a diluent.

Bacterial strains. The bacterial strains used are listed in Table 1. Gene symbols except for newly identified genes are those used by Bachmann et al. (1976) and most allele numbers have been assigned by the Coli Genetic Stock Center. Allele numbers for certain mutations recently isolated or in strains not previously used have not yet been assigned. Table 2 lists the map positions, if known, for genes used in strain construction. The genealogies of x_{1276} (the ancestral parent to x_{1776} and x_{2076}) and x_{1038} (the ancestral parent to x_{1972} and x_{1976}) are given in Charts A and B, respectively. The strains were maintained on Penassay agar slants (supplemented with thymidine and/or DAP if necessary) at 4°C. when in routine use and in 1% peptone-5% glycerol (supplemented as above if necessary) at -70°C. for long-term storage.

Bacteriophages. T1, T2, T3, T4, T5, T6, T7, $\phi 12$, $\phi 14$ and the F⁻ specific phages ϕII , PV, ϕW and ϕH were propagated on *E. coli* B (x_{8}) λ , 434, 21, $\phi 80$ and their derivatives were induced from lysogens or propagated on x_{289} or x_{1918} . S13 was

propagated on *E. coli* C (695). The F donor-specific phages fl, MS—2, Q β , R17 and fcan1 were propagated on x1365 and the I donor-specific phage If2 on x1005. Mu, BF23, P1L4, D108 and K3 were propagated on x289 as were the rough-specific phages, 6SR, Ffm, Br60, FPI, FP3 and Br10. C21 was propagated on a *galE Salmonella typhimurium* LT2 strain (x1890). All phages were propagated and assayed using the appropriate media containing the optimal concentrations of Na⁺, Mg⁺⁺ or Ca⁺⁺. Certain of the above-mentioned phages or their derivatives were propagated on other host strains, especially for use in transduction, testing of restriction-modification and suppressor phenotypes, etc. as indicated in the text. General methods for phage work were as described by Adams (1959).

Transduction. P1L4 was propagated on appropriate donor strains. Transduction was accomplished by adding P1L4 to a multiplicity of about 3 per bacteria (actual moi of about one) to recipient bacteria at about 2×10^8 /ml that had grown for 90 to 120 min in L broth containing 2.5×10^{-3} M CaCl₂. After 20 to 30 min at 37°C., samples were plated on appropriate selective media or when phenotypic and/or segregation lag problems were anticipated the culture was diluted 100 to 1000 fold into appropriate liquid media containing 10^{-2} M citrate and allowed to grow at 37°C. until titers of 10^8 cells/ml were achieved prior to plating.

Mutagenesis and mutant enrichment techniques. Mutations that were used in strain construction were either spontaneous or induced by nitrous acid, ultraviolet light (UV), nitrosoguanidine or nitrogen mustard. Cell survival following mutagen treatment was always 10 percent or higher to minimize the possibility of multiple mutational events. Introduction of mutations by mutagenesis and/or transduction was usually followed by two cycles of enrichment using 100 μ g cycloserine/ml plus 100 μ g ampicillin/ml when direct selection for inheritance of the mutation was not possible. Spontaneous *thyA* mutants were enriched by the use of trimethoprim.

Conjugation. Optimal conditions for growing strains to maximize expression of the donor and recipient phenotypes and for carrying out matings were used.

Minicell production. Throughout the construction of x1776 and x2076, good minicell-producing isolates were chosen as the derivative of choice. Minicell production was assessed by microscopic examination of late log-phase cultures. The ratio of minicells to normal cells and the frequency of cells in the act of producing minicells were used in determining the choice.

Minicells were purified quantitatively for some experiments by the double sucrose gradient purification technique described by Frazer and Curtiss (1975).

Growth. Conscious selection was made for good growth at each step in the constructions. Growth in various media was monitored spectrophotometrically with all cultures grown and monitored at 37°C.

TABLE 1.
Bacterial Strains.

Strain Number	Mating Type	Genotype ^a	Derivation or Source
x ₈	F ⁻	<i>E. coli</i> B prototroph	—
x ₁₅	F ⁺	<i>supE42</i> λ ⁻ T3 ^r	W1485 (Curtiss, 1964)
x ₂₈₉	F ⁻	<i>supE42</i> λ ⁻ T3 ^r	15 by acridine orange curing (Curtiss et al., 1965)
x ₄₈₇	F ⁻	<i>leu-6 tonA2 lacY1 tsx-1 supE44 gal-6</i> λ ⁻ <i>his-1 argG6 rps L104 malT1 xyl-7 mtl-2 metB1</i>	JC411 (see Bachmann, 1972)
x ₄₈₉	F ⁻	<i>leu-6 tonA2 lacY1 tsx-1 supE44 gal-6</i> λ ⁻ <i>his-1 recA1 argG6 rpsL104 malT1 xyl-7 mtl-2 metB1</i>	From x ₄₈₇
x ₅₀₉	F ⁻	<i>supE42</i> λ ⁻ T3 ^r <i>xyl-14 cycB2 cycA1</i>	Spontaneous from x ₃₂₃ (Curtiss et al., 1965)
x ₅₁₀	F ⁻	<i>supE42</i> λ ⁻ <i>his-53 T3^r xyl-14 cycB2 cycA1</i>	UV-induced from x ₅₀₉
x ₅₂₀	F ⁻	<i>tsx-63 supE42</i> λ ⁻ <i>his-53 T3^r xyl-14 cycB2 cycA1</i>	spontaneous from x ₅₁₀
x ₅₂₈	F ⁻	<i>tsx-63 supE42</i> λ ⁻ <i>his-53 lysA32 T3^r xyl-14 cycB2 cycA1</i>	UV-induced from x ₅₂₀
x ₅₃₆	Hfr OR11	<i>supE42</i> λ ⁻ <i>serA12 T3^r</i>	Nitrogen mustard-induced from x ₄₉₃ (Berg and Curtiss, 1967)
x ₅₄₀	F ⁻	<i>tsx-63 purE41 supE42</i> λ ⁻ <i>pyrF30 his-53 T3^r xyl-14 cycB2 cycA1</i>	UV-induced <i>purE</i> from x ₅₂₉ which was UV-induced <i>pyrF</i> from x ₅₂₀ (Curtiss et al., 1968)
x ₅₅₉	Hfr OR11	<i>leu-45 supE42</i> λ ⁻ <i>ΔthyA57 T3^r</i>	Aminopterin selected from x ₅₃₄ (Berg and Curtiss, 1967)
x ₅₆₉	F ⁻	<i>tsx-63 supE42</i> λ ⁻ <i>his-53 lysA32 T3^r xyl-14 arg-65 cycB2 cycA1</i>	UV-induced from x ₅₂₈
x ₅₇₃	F ⁺ ORF—4	F <i>lac⁺ proC⁺ tsx⁺ purE⁺/Δ[lac-purE] supE42</i> λ ⁻ <i>serA12 T3^r</i>	From x ₅₃₆

Table 1 (continued).

Strain Number	Mating Type	Genotype ^a	Derivation or Source
x ⁵⁸⁴	Hfr OR41	$\Delta 41[pro-lac] supE42 \lambda^- thyA80 T3^+ cycA1 deo-33$	Spontaneous from x ⁵⁹³ which was derived from x ⁵⁸³ by introduction of F from x ¹⁵ . x ⁵⁸³ was aminopterin selected from x ³⁵⁴ (Curtiss et al., 1968)
x ⁶⁰²	Hfr OR38	$supE42 \lambda^- T3^+$	Spontaneous from x ¹⁵ (Curtiss et al., 1974)
x ⁶⁵⁶	F ⁻	$thr-16 tsx-63 purE41 supE42 \lambda^- pyrF30 his-53 T3^+ xyl-14 cycB2 cycA1$	UV-induced from x ⁵⁴⁰
x ⁶⁶⁰	F ⁻	$tsx-63 purE41 supE42 \lambda^- pyrF30 his-53 T3^+ argB15 xyl-14 cycB2 cycA1$	UV-induced from x ⁵⁴⁰
x ⁶⁷⁵	F ⁻	$tsx-63 purE41 supE42 \lambda^- pyrF30 his-53 T3^+ xyl-14 cycB2 cycA1 serB31$	UV-induced from x ⁵⁴⁰
x ⁷²²	Hfr OR11	$supE42 \lambda^- pyr-61 T3^+$	UV-induced from x ⁴⁹³ (Berg and Curtiss, 1967)
x ⁸²⁸	F ⁻	$F-his^+/leu-6 lacY1 gal-6 \lambda^- sup-59 his-1 argG6 rpsL104 malT1 xyl-7 mtl-2 metB1$	From E. Goldschmidt
x ⁸³²	F ⁻	$thr-16 lacY29 proC24 tsx-63 purE41 supE42 \lambda^- pyrF30 his-53 rpsL97 T3^+ xyl-14 cycB2 cycA1$	UV-induced from x ⁸²⁰ (Curtiss et al., 1968). The <i>thr</i> allele was UV-induced in x ⁵⁴⁰ to yield x ⁶⁵⁶ and a spontaneous <i>rpsL</i> mutation was selected to give x ⁷²³ . The <i>proC</i> allele was UV-induced to give x ⁸²⁰ .
x ⁸⁴⁶	F ⁻	$thr-16 lacY29 proC24 tsx-63 purE41 supE42 \lambda^- pdxC3 pyrF30 his-53 rpsL97 T3^+ xyl-14 cycB2 cycA1$	UV-induced from x ⁸³²
x ⁸⁴⁹	F ⁻	$thr-16 tonA32 lacY29 proC24 tsx-63 purE41 supE42 \lambda^- pdxC3 pyrF30 his-53 rpsL97 T3^+ xyl-14 cycB2 cycA1$	Spontaneous from x ⁸⁴⁶
x ⁹⁰⁹	F ⁺	$supE42 (?) \lambda^- dnaB43(TS)$	Stallions and Curtiss (1971)
x ⁹¹⁹	F ⁻	$\lambda^- lysA endA1 met$	From J. Hurwitz
x ⁹²⁹	F ⁻	$thr-16 car-33 tonA32 lacY29 proC24 tsx-63 purE41 supE42 \lambda^- pdxC3 pyrF30 his-53 rpsL97 T3^+ xyl-14 cycB2 cycA1$	UV-induced from x ⁸⁴⁹

Table 1 (continued).

Strain Number	Mating Type	Genotype	Derivation or Source
\times 930	F ⁻	<i>thr-16 car-33 tonA32 lacY29 proC24 tsx-63 purE41 supE42 λ^- pdxC3 pyrF30 his-53 rpsL97 T3⁺ xyl-14 ilv-277 cycB2 cycA1</i>	UV-induced from \times 929
\times 961	F ⁻	<i>thr-16 car-33 tonA32 lacY29 proC24 tsx-63 purE41 supE42 λ^- pdxC3 pyrF30 his-53 metC65 rpsL97 T3⁺ xyl-14 ilv-277 cycB2 cycA1</i>	UV-induced from \times 930
\times 1005	R64—11 ⁺	<i>drd11 Sm^r Tc^r/pro-2 metF63</i>	From G. Meynell
\times 1037	F ⁻	<i>lacY1 supE44 galK2 galT22 met B1 hsdR2</i>	802 (Kellenberger et al., 1966; Wood, 1966)
\times 1038	F ⁻	<i>lacY1 supE44 galK2 galT22 metB1 hsdS3</i>	803 (Kellenberger et al., 1966; Wood, 1966)
\times 1087	F ⁻	prototroph <i>supF58</i> (= <i>tyrT58</i>)	From I. P. Crawford as Y mel
\times 1091	F ⁻	<i>λ^- thyA36</i>	Derived from W3110 (see Bachmann, 1972)
\times 1272	Hfr KL16	<i>dapD8 λ^- relA1 thi-1</i>	AT986 (Bukhari and Taylor, 1971)
\times 1365	Hfr Q13	<i>rna-19 his-95 tyr-6 relA1 pnp-13 metB1</i>	Reiner (1969)
\times 1487	F ⁺	<i>lacY1 supE44 galK2 galT22 metB1 hsdR2</i>	\times 15 \times \times 1037
\times 1525	F ⁻	<i>λ^- ΔtrpE63 tna</i>	Derived from W3110 (see Bachmann, 1972)
\times 1634	F ⁻	<i>thr-16 tsx-63 purE41 supE42 λ^- ΔtrpE63 his-53 T3⁺ xyl-14 cycB2 cycA1</i>	P1L4 (\times 1525 transduction of \times 656
\times 1652	Hfr G6	<i>his-323 T3⁺ Δ29(bioH-asd)</i>	From M. Hofnung
\times 1653	Hfr AB313	<i>leu-6 lacZ4 srl-1 rpsL8 milA9 thi-1</i>	From W. Epstein
\times 1656	Hfr KL16	<i>tonA53 dapD8 λ^- relA1 thi-1</i>	Spontaneous from \times 1272
\times 1674	Hfr AB313	<i>leu-6 lacZ4 nalB srl-1 rpsL8 milA9 thi-1</i>	Spontaneous from \times 1653
\times 1676	F ⁻	<i>thr-16 tsx-63 purE41 supE42 λ^- ΔtrpE63 his-53 T3⁺ xyl-14 metE98 cycB2 cycA1</i>	P1L4 (\times 1108) transduction of \times 1634 with ampicillin-cycloserine enrichment

Table 1 (continued).

Strain Number	Mating Type	Genotype	Derivation or Source
\times 1692	F ⁻	<i>thr-16 tsx-63 purE41 supE42 λ^- ΔtrpE63 his-53 T3⁺ mtlA9 metE98 cycB2 cycA1</i>	P1L4 (\times 1674) transduction of \times 1676
\times 1707	F ⁻	<i>leu-6 tonA2 lacY1 tsx-1 gal-6 λ^- his-1 supE44 rpsL104 maltI xyl-7 mtl-2 argG6 metB1 nalB recA1</i>	Spontaneous from \times 489
\times 1712	F ⁻	<i>thr-16 tsx-63 purE41 supE42 λ^- ΔtrpE63 his-53 srl-2 T3⁺ mtlA9 metE98 cycB2 cycA1</i>	UV-induced from \times 1692
\times 1715	F ⁻	Δ 41[<i>pro-lac</i>] <i>supE42 λ^- his-53 T3⁺ xyl-14 cycB2 cycA1</i>	\times 584 \times \times 510
\times 1717	F ⁻	<i>thr-16 tsx-63 purE41 supE42 λ^- ΔtrpE63 his-53 srl-2 nalB⁺ T3⁺ mtlA9 metE98 cycB2 cycA1</i>	Spontaneous from \times 1712
\times 1753	F ⁻	<i>tsx-63 supE42 λ^- his-53 lysA32 T3⁺ xyl-14 arg-65</i>	\times 722 \times \times 569
\times 1763	F ⁻	Δ 41[<i>pro-lac</i>] <i>supE42 λ^- his-53 nalA T3⁺ xyl-14 cycB2 cycA1</i>	Spontaneous from \times 1715
\times 1770	F ⁻	<i>supE42 λ^- T3⁺ maltT44</i>	Spontaneous by λ vir selection from \times 289
\times 1795	F ⁻	<i>supE42 λ^- T3⁺ aroB15</i>	P1L4 (\times 660) transduction of \times 1770
\times 1801	F ⁻	<i>leu-6 tonA2 lacY1 λ^- his-1 non-9 argG6 maltI xyl-7 mtl-2 metB1</i>	From E. Siegel
\times 1821	Hfr OR11	<i>supE42 λ^- endA1 T3⁺</i>	P1L4 (\times 919) on \times 536
\times 1825	F ⁻	<i>supE42 λ^- T3⁺ Δ29 [bioH-<i>asd</i>]</i>	P1L4 (\times 1652) transduction of \times 1795
\times 1833	F ⁻	<i>supE42 λ^- nalA27 T3⁺</i>	Spontaneous from \times 289
\times 1841	F ⁻	<i>minA1 purE41 supE42 λ^- pdxC3 minB2 his-53 nalA28 metC65 rpsL97 T3⁺ xyl-14 ilv-277 cycB2 cycA1 hsdR2</i>	Spontaneous from \times 1488 (see Chart C)

Table 1 (continued).

Strain Number	Mating Type	Genotype	Derivation or Source
\times 1857	F ⁻	<i>leu-6 tonA2 lacY1</i> λ^- <i>non-9 argG6 malT1 xyl-7 mtl-2 metB1</i>	P1L4 (\times 289 transduction of \times 1801
\times 1890	F ⁻	<i>Salmonella typhimurium</i> LT-2 <i>met-22 galE409 trpB2 H1-b H2-e, n, x</i>	SL869 from R. T. Jones
\times 1918	Hfr H	<i>lacZ</i> (ochre) λ^- <i>relA1 rpsL metB1 argE</i> (amber)	SC180 from O. Reyes
\times 1919	Hfr H	<i>lacZ</i> (ochre) λ^- <i>relA1 rpsL metB1 argE</i> (amber) <i>tyrT</i>	SC183 from O. Reyes
\times 1922	F ⁻	<i>supE42</i> λ^- <i>nalA27</i> Δ <i>thyA57</i> T3 ⁺	P1L4 (\times 559) transduction of \times 1833 with trimethoprim selection
\times 1991	F ⁻	<i>thr-16 tsx-63 purE41 supE42</i> λ^- Δ <i>trpE63 non-9 srl-2</i> Δ <i>thyA57 endA1</i> T3 ⁺ <i>aroB15 mtlA9 metE98 cycB2 cycA1</i>	Derived from \times 1712
\times 2017	F ⁺	F <i>lac</i> ⁺ Δ <i>lacZ trp</i>	R. Goldschmidt
\times 2050	F ⁻	<i>thr-16 tsx-63 purE41 supE42</i> λ^- Δ <i>trpE63 non-9 nalA srl-2</i> Δ <i>thyA57 endA1</i> T3 ⁺ <i>aroB15 mtlA9 metE98 cycB2 cycA1</i>	Spontaneous nalidixic acid resistant
\times 2051	F ⁻	<i>thr-16 tsx-63 purE41 supE42</i> λ^- Δ <i>trpE63 non-9 nalA dapA</i> or <i>E srl-2</i> Δ <i>thyA57 endA1</i> T3 ⁺ <i>aroB15 mtlA9 metE98 cycB2 cycA1</i>	Nitrous acid mutagenesis with Amp.-Cyc. enrichment from \times 2050
\times 2055	F ⁻	<i>thr-16 tsx-63 purE41 supE42</i> λ^- Δ <i>trpE63 non-9 nalA dap upp srl-2</i> <i>thyA57 endA1</i> T3 ⁺ <i>aroB15 mtlA9 metE98 cycB2 cycA1</i>	Spontaneous 5'-F-uracil resistant of \times 2051
\times 2056	F ⁻	<i>supE42</i> λ^- <i>nalA27</i> Δ <i>thyA57</i> T3 ⁺ Δ <i>deoA</i>	Nitrous acid mutagenesis of \times 1922
\times 2057	F ⁻	<i>thr-16 tsx-63 purE41 supE42</i> λ^- Δ <i>trpE63 non-9 srl-2</i> Δ <i>thyA57 endA1</i> T3 ⁺ <i>aroB15 mtlA9 metE98 polA(CS) cycB2 cycA1</i>	Nitrosoguanidine mutagenesis of \times 1991
\times 2058	F ⁻	<i>thr-16 tsx-63 purE41 supE42</i> λ^- Δ <i>trpE63 non-9 srl-2</i> Δ <i>thyA57 endA1</i> T3 ⁺ <i>aroB15 mtlA9 polA(CS) cycB2 cycA1</i>	P1L4 (\times 289) transduction of \times 2057

* Allele numbers have in general been assigned by the Coli Genetic Stock Center.

TABLE 2.

Gene Loci Used in Construction of Strains^a

Gene Symbol	Map Position (min)	Alternate gene symbols; phenotypic trait affected
<i>thr</i>	0.0	threonine requirement
<i>car</i>	0.6	<i>arg + ura, cap, pyrA</i> ; carbamoylphosphate synthetase
<i>ara</i>	1.3	utilization of arabinose
<i>leu</i>	1.7	leucine requirement
<i>azi</i>	2.1	<i>pea</i> ; resistance or sensitivity to sodium azide or phenethyl alcohol; filament formation at 42°C.
<i>tonA</i>	3.45	resistance to phages T1 and T5
<i>dapD</i>	3.65	diaminopimelic acid requirement
<i>lpcA</i>	5.5	<i>tfrA</i> ; defective in synthesis of LPS core and resistance to phages T3, T4, T7, λ and P1
<i>proA</i>	5.6	proline requirement
<i>lacY</i>	7.8	galactose permease (M protein)
<i>proC</i>	8.7	probably Δ -pyrroline-5-carboxylate reductase
<i>tsx</i>	9.0	resistant to phage T6
<i>minA</i>	9.85	formation of minicells
<i>purE</i>	11.7	purine requirement
<i>rna</i>	13.8	<i>rns, rnsA</i> ; ribonuclease I
<i>con</i>	14.25	conjugation deficiency
<i>supE</i>	14.9	Su II; suppressor of amber mutations
<i>galKTEO</i>	16.7	utilization of galactose and for <i>galE</i> inability to synthesize colanic acid and incorporate galactose in LPS side chain
<i>chlD</i>	16.8	resistance to chlorate anaerobically; activation of nitrate reductase by molybdate
<i>phr</i>	16.9	photoreactivating enzyme
<i>attλ, 82, 434</i>	16.95	integration sites for λ and phages 82 and 434
<i>bioA—D</i>	17.2	biotin requirement
<i>uvrB</i>	17.3	defective in excision repair and UV sensitive
<i>chlA</i>	17.3	resistance to chlorate anaerobically; effects nitrate reductase and hydrogen lyase activity

TABLE 2 (continued).

Gene Symbol	Map Position (min)	Alternate gene symbols; phenotypic trait affected
<i>pdxC</i>	19.8	pyridoxine requirement
<i>tyrT</i>	26.7	<i>supF</i> ; tyrosyl-transfer RNA synthetase 1
<i>galU</i>	26.8	uridinediphosphoglucose pyrophosphorylase; unable to synthesize colanic acid
<i>trpE</i>	27.4	<i>anth</i> , <i>tryp-4</i> , <i>tryD</i> ; anthranilate synthetase, large subunit
<i>pyrF</i>	27.9	pyrimidine (uracil) requirement
<i>minB</i>	~29	formation of minicells
<i>his</i>	44.2	histidine requirement
<i>rfaA, B, D</i>	44.75	rough phenotype lacking rhamnose in LPS side chain
<i>nalA</i>	47.95	resistance to 50—100 μ g nalidixic acid/ml
<i>dapE</i>	52.6	<i>dapB</i> ; N-succinyl-diaminopimelate deacylase
<i>dapA</i>	52.65	dihydrodipicolinate synthetase
<i>upp</i>	53.5	<i>uraP</i> ; uridine monophosphate phosphorylase
<i>recA</i>	57.6	<i>rech</i> , <i>tif</i> , <i>zab</i> ; competence for genetic recombination and repair of radiation damage
<i>srl</i>	57.75	sorbitol uptake and utilization
<i>relA</i>	59.2	RC; regulation of RNA synthesis
<i>oms-2</i>	~60.2	outer membrane structure modification
<i>thyA</i>	60.5	thymidine requirement; thymidylate synthetase
<i>lysA</i>	60.75	diaminopimelate decarboxylate
<i>serA</i>	62.3	serine or glycine requirement
<i>can</i>	62.4	canavanine resistance
<i>endA</i>	63.2	DNA specific endonuclease I
<i>metC</i>	63.95	methionine requirement
<i>lpcB</i>	65	<i>pon</i> ; defective in synthesis of LPS core and resistant to phages T4 and P1
<i>oms-1</i>	64—72	outer membrane structure modification
<i>pnp</i>	67.8	polynucleotide phosphorylase
<i>argG</i>	67.9	argininosuccinate synthetase
<i>envB</i>	70.1	<i>mon</i> ; anomalous spheroid cell formation

TABLE 2 (continued).

Gene Symbol	Map Position (min)	Alternate gene symbols; phenotypic trait affected
<i>rpsL</i>	72.05	<i>str</i> ; resistance to streptomycin
<i>aroB</i>	73.45	shikimic acid requirement
<i>bioH</i>	74.7	biotin requirement
<i>malA</i>	74.0	utilization of maltose
<i>malT</i>	74.0	regulatory gene controlling genes for utilization of maltose and resistance to phage λ
<i>asd</i>	74.3	requirement for diaminopimelic acid and homoserine (or threonine plus methionine); aspartic acid semialdehyde dehydrogenase
<i>xyl</i>	78.8	utilization of xylose
<i>mtlA</i>	79.55	utilization of mannitol; mannitol-semispecific enzyme II of phosphotransferase system
<i>rfa</i>	~80	defective in LPS core synthesis
<i>ilv</i>	83.2	isoleucine and valine requirements
<i>metE</i>	84	<i>met-B₁₂</i> ; N ⁵ -methyltetrahydropteroyl tri-glutamate-homocysteine methylase
<i>polA</i>	84.95	<i>resA</i> ; DNA polymerase I
<i>metB</i>	87.3	<i>met-1</i> , <i>met₁</i> ; cystathionine synthetase
<i>metF</i>	87.3	<i>met-2</i> , <i>met₂</i> ; N ⁵ -N ¹⁰ -methylene-tetrahydro-folate reductase
<i>thi</i>	89.0	requirement for thiamine (Vit B ₁)
<i>dnaB</i>	91.2	<i>exrB</i> ; <i>groP</i> ; DNA synthesis
<i>cycB</i>	93	resistance to 5—15 μ g D-cycloserine/ml; defective in growth on D-alanine or L-alanine
<i>cycA</i>	94	<i>dagA</i> ; resistance to 1.5—3 μ g D-cycloserine/ml; defective in transport of D-alanine, D-serine and glycine
<i>hsdR</i>	98.5	<i>hsr</i> ; restriction endonuclease
<i>hsdS</i>	98.5	<i>hss</i> ; site-specific protein for restriction-modification system
<i>deoC</i>	99.45	<i>dra</i> ; thymine utilized efficiently; phospho-deoxyriboaldolase; confers sensitivity to 1 mM thymidine and purine deoxyribo-nucleosides
<i>deoA</i>	99.46	<i>tpp</i> ; <i>TP</i> ; thymidine phosphorylase

TABLE 2 (continued).

Gene Symbol	Map Position (min)	Alternate gene symbols; phenotypic trait affected
<i>deoB</i>	99.5	<i>drm</i> ; thymine utilized efficiently; phosphodeoxyribonmutase
<i>serB</i>	99.6	phosphoserine phosphatase

*Gene symbols and map positions are taken from Bachmann, Low and Taylor (1976). Note that the *E. coli* genetic map has been expanded from 90 min to 100 min.

CHART A.

GENEALOGY OF λ 1276^a

5	PA678 Str ^r Azi ^r	F ⁻ <i>thr-1 ara-13 leu-6 azi-8 tonA2 lacY1 supE44 gal-6 λ^- minB2 rpsL135 malA1 xyl-7 mtl-2 thi-1</i>	5
	↓	Triethylenemelamine sel'n.	
	P678—54	F ⁻ <i>thr-1 ara-13 leu-6 azi-8 tonA2 lacY1 minA1 supE44 gal-6 λ^- minB2 rpsL135 malA1 xyl-7 mtl-2 thi-1</i>	
10	↓	single colony isolated for high minicell production	10
	λ 925	F ⁻ <i>thr-1 ara-13 leu-6 azi-8 tonA2 lacY1 minA1 supE44 gal-6 λ^- minB2 rpsL135 malA1 xyl-7 mtl-2 thi-1</i>	
15	↓	X _x 909 with sel'n. for Gal ⁺ Str ^r recombinants	15
	λ 911	F ⁺ & F ⁻ <i>leu-6 minA1 supE42 λ^- minB2 rpsL135 malA1 xyl-7 mtl-2 thi-1 dnaB43 (TS)</i>	
20	↓	X _x 536 with sel'n. for Thr ⁺ Leu ⁺ Thi ⁺ Ser ⁺ recombinants	20
	λ 964	F ⁺ <i>minA1 supE42 λ^- minB2</i>	
	λ 961	F ⁻ <i>thr-16 can-33 tonA32 lacY29 proC24 tsx-63 purE41 supE42 λ^- pdxC3 pyrF30 his-53 metC65 rpsL97 T3^r xyl-14 ilv-277 cycB2 cycA1</i>	
25	↓	X _x 964 with sel'n. for Lac ⁺ Pyr ⁺ Str ^r recombinants	25
	λ 984	F ⁻ <i>minA1 tsx-63 purE41 supE42 λ^- pdxC3 minB2 his-53 metC65 rpsL97 T3^r xyl-14 ilv-277 cycB2 cycA1</i>	
30	↓	UV treatment	30
	λ 1276	F ⁻ <i>ara-40 minA1 tsx63 purE41 supE42 λ^- pdxC3 minB2 his-53 metC65 rpsL97 T3^r xyl-14 ilv-277 cycB2 cycA1</i>	

^aPA 678 Str^r Azi^r from P678 (see Bachmann, 1972). P678—54 isolated by Adler et al. (1967). Both of these strains are on deposit and available from the Coli Genetic Stock Center, Yale University, New Haven, Connecticut, U.S.A. Other steps in derivation of λ 1276 given by Frazer and Curtiss (1975). See Table 1 for origins of λ 909, λ 536 and λ 961.

CHART B.

GENEALOGY OF λ 1038.

40	Arber 101 (C600)	F ⁻ <i>thr-1 leu-6 tonA21 lacY1 λ^- supE44 thi-1</i>	40
	↓	X Arber 151 (W4032) Hfr <i>pro-3 lac-3 [DE 6] rel-1 metB1</i> with sel'n. for Thr ⁺ Leu ⁺ Thi ⁺ Pro ⁺	
	Arber 612	F ⁻ <i>lacY1 supE44 λ^- metB1</i>	
	↓	PI (Arber 144: F ⁻ <i>galK2 galT22 malT</i>) with pen. enrichment	
45	Arber 704	F ⁻ <i>lacY1 supE44 galK2 galT22 λ^- metB1</i>	45
	↓	spontaneous mutation; infection with λ dg. B and λ cb2; sel'n. of Gal ⁻ non-lysogenic segregants	
	Arber 803	F ⁻ <i>supE44 galK2 galT22 λ^- metB1 hsdS3</i>	

Arber 803 also called KH803 is $\times 1038$ in the Curtiss *E. coli* collection (see Table 1). The development of Arber 803 and the derivations of Arber 101 and Arber 151 are described by Kellenberger et al. (1966) and Wood (1966).

GENETIC MODIFICATION OF MICROORGANISMS.

5 Construction of $\times 1776$. Chart C gives the genealogy of $\times 1776$ from $\times 1276$ (see Chart A). $\times 1276$ was selected as the starting point because it (i) possessed genetic markers that were thought to be useful in strain construction or to provide safety benefits, (ii) had 80 to 90% of its chromosome derived from W1485 and (iii) produced minicells that would be useful in studying expression of plasmid chimeras. The principal goal in constructing $\times 1776$ was to determine whether a given constellation of genetic markers would block cell wall biosynthesis and preclude survival in non-laboratory controlled environments. The goal to maintain isogenicity to W1485 was therefore sacrificed on several occasions for sake of expediency. At each step in the construction, a conscious effort was made to select clones that grew most rapidly and produced the highest yields and purity of minicells. 10 15

The first step was to introduce the *hsdR2* allele into $\times 1276$ to eliminate the K-12 restriction system and thus enable introduction of foreign DNA sequences into the strain. This was accomplished by conjugation with $\times 1487$, an F^+ derivative of $\times 1037$, in a mating of short duration (10 min) with a 1 to 5 donor to recipient ratio so that a high frequency of the $Ara^+ Str^r$ recombinants would remain F^- . A rapidly growing, high minicell-producing $F^- Ara^+ Str^r$ recombinant that failed to restrict λvir grown in $\times 1038$ (Table 1) was stocked as $\times 1488$. Since $\times 1487$ is a non W1485 derived strain, from 3 to 10 minutes of the $\times 1488$ chromosome was replaced with non-W1485 derived information. In the second step, the *rpsL97* (*str^r*) allele in $\times 1488$ was removed so that plasmid cloning vectors with Sm^r as a selectable trait could be used in the strain. This was accomplished by conjugation with $\times 602$ (Table 1), a W1485 derived Hfr, to yield $\times 1678$. The removal of the *rpsL97* allele in this and other strains was accompanied by a slight but measurable lengthening of the generation time. 20 25 30

The next goal was to abolish the ability of the strain to synthesize the rigid layer of its cell wall in other than carefully controlled laboratory environments. Since diaminopimelic acid (DAP) is a unique constituent of the mucopeptide of the rigid layer of the cell wall in most Gram-negative bacteria and since DAP is not known to be synthesized by eukaryotic organisms, it was considered that free DAP should not be prevalent in nature and therefore that Dap⁻ mutants should undergo lysis and not survive in nature. After screening numerous *dap* alleles for genetic stability, the *dapD8* marker which was induced by nitrosoguanidine was selected as the least revertible (ca. 10^{-9} revertant frequency) for introduction into $\times 1678$. This was accomplished by cotransduction of *dapD8* with the *tonA53* marker (90% cotransducible). $\times 1678$ was permitted to grow in L broth + DAP for 9 generations following transduction with P1L4 ($\times 1656$ before challenging with a high multiplicity of T5. The introduction of the *dapD8* allele into $\times 1678$ to yield $\times 1697$ was accompanied by a lesion conferring thermosensitivity which was later found to be present in $\times 1656$ and some but not all of the T5 *dapD8* transductants obtained from $\times 1678$. This TS defect was eliminated by spontaneous reversion to yield $\times 1702$. 35 40 45

$\times 1702$ was subjected to numerous tests with disappointing results. It did not undergo an appreciable frequency of DAP-less death in L broth, Penassay broth or ML (with or without Casamino acids) that lacked DAP and actually could grow in these media. It also survived passage through the intestinal tract of the rat (see later) and was a proficient recipient in matings with R^+ donors. The initial belief was that the *dapD8* allele was not only revertible but leaky. A search for other stable mutations conferring a Dap⁻ phenotype was therefore initiated while continuing studies on the properties of $\times 1702$. It was soon observed that $\times 1702$ did undergo DAP-less death at 42°C. in all media lacking DAP and that it could form colonies on L and Penassay agars lacking DAP at 30° and 37°C. but not at 42°C. These colonies were mucoid. By replica plating tests it was determined that the number of colonies which replicated to media without DAP increased as the DAP concentration in the master plates decreased. It was also observed that the omission of NaCl from the L or Penassay agar lacking DAP precluded colony formation and that in liquid media lacking DAP the omission of NaCl also led to better rates of DAP-less death and inability of $\times 1702$ to grow in the absence of DAP. It was then determined that the ability of $\times 1702$ to grow in liquid media containing NaCl but lacking DAP was due to the formation of spheroplasts that 50 55 60

were surrounded by a mucopolysaccharide capsule which must act as a stabilizer against the osmotic pressure differences between the cell cytoplasm and the surrounding medium. The mucoid colonies forming on solid media lacking DAP were also composed of capsule surrounded spheroplasts. By this time it appeared certain that $\times 1702$ and some other Dap⁻ strains were producing colanic acid whose synthesis is (i) regulated by the *lon* (*capR*) gene, (ii) prevented by incubation at 42°C. and (iii) stimulated by presence of NaCl and adverse environments during cell growth. It thus became apparent that it would be necessary to eliminate the ability to produce colanic acid to obtain a strain that could neither synthesize a cell wall nor survive in other than carefully controlled laboratory environments.

During these studies, $\times 1702$ was manipulated in three steps (Chart C) to give rise to $\times 1845$ which possesses the $\Delta 29[\text{bioH-} \text{asd}]$ deletion which also confers a Dap⁻ phenotype because of the inability to synthesize homoserine semi-aldehyde. $\times 1845$, like $\times 1702$, can produce colanic acid and survive in the absence of DAP under the appropriate conditions although it is unable to revert to DAP⁺. A spontaneous high-level nalidixic acid resistant mutant was selected to facilitate retrieval of the strain during rat feeding tests. This was done by plating a concentrated $\times 1845$ culture on L agar containing DAP and 100 μg nalidixic acid/ml. $\times 1846$ presumably has a mutation in the *nalA* gene since this is the only locus known in which mutations confer high-level resistance to nalidixic acid. $\times 1846$ was then mutagenized by nitrous acid treatment and after sufficient growth to permit segregation and expression, was plated on MacConkey agar containing DAP, adenine, galactose, and 0.2% KClO₃. These plates were incubated anaerobically in a BBL Gas-Pak jar to obtain Gal⁻ Chl^r mutants that would be unable to synthesize colanic acid. The $\Delta 40[\text{gal-} \text{uvrB}]$ deletion induced in $\times 1846$ to yield $\times 1849$ does block colanic acid synthesis and at the same time confers high UV sensitivity, abolishes photoreactivation and diminishes lysogenization by λ , 82 and 434. $\times 1849$ was shown to be unable to survive in the absence of DAP and exhibited good rates of DAP-less death although it still could survive passage through the rat intestine and was proficient as a recipient for some but not all conjugative R plasmids. It was thus decided to remove the *his-53*, *purE41* and *ilv-277* alleles since they might tend to reduce growth rates in non-laboratory environments and thus diminish either the rates or likelihood of DAP-less death. It should be noted that although studies in mice some ten years ago indicated that *pur* mutations were detrimental to bacterial survival and/or colonization of the intestinal tract (Jones and Curtiss, unpublished), such effects with *pur*⁻ strains were not observed in experiments in which strains were fed to rats.

Comcomitant with the removal of the *his-53* allele to yield $\times 1855$, another mutation was introduced that results in sensitivity to bile salts and detergents, increases sensitivity to numerous antibiotics, alters phage sensitivity patterns and reduces recipient ability in matings with donors possessing several different R plasmid types. It is believed that this lesion is in either the *rfbA* or *rfbB* locus both of which are cotransducible with the *his* locus. The basis for this belief as well as the dependence of the phenotype due to this mutation on the presence of at least one additional mutation in $\times 1849$ that is designated *oms-1* has been substantiated. The combined effects of the *rfb-2* and *oms-1* mutations also result in a Con⁻ recipient phenotype, increased resistance to various phages and sensitivity to bile salts, antibiotics, etc. $\times 1855$ and its descendants are also thermosensitive, being unable to form colonies at 42°C. $\times 1849$ and its ancestors (except for $\times 1697$) plate normally at 42°C.

The removal of the *purE41* and *ilv-277* alleles by transduction with P1L4 ($\times 289$) to yield $\times 1864$ (Chart C) was accomplished without great difficulty. It should be mentioned that although $\times 1855$ and $\times 1859$ were partially resistant to P1L4 due to the *oms-1* and *rfb-2* mutations introduced into $\times 1849$ and $\times 1855$, the transducibility of these strains was only reduced 5- to 10-fold compared to $\times 1849$ and the frequencies of Ilv⁺ and Pur⁺ transductants were still far in excess of the reversion frequencies.

Since *thyA* mutations lead to thymineless death and degradation of DNA in media lacking thymine and diminish survival of strains during passage through the rat intestine, it was decided to introduce the *thyA57* mutation from $\times 559$ (Table 1) into $\times 1864$ as the last step in constructing $\times 1776$. The *thyA57* allele was selected since it had never been observed to revert either in $\times 559$ or in any other strain into which the allele had been introduced. However, the introduction of this mutation into $\times 1864$ proved to be difficult and probably was not in reality achieved. After permitting 30 minutes for P1L4 ($\times 559$) adsorption to $\times 1864$ in L broth + DAP + 2.5

$\times 10^{-3}$ M CaCl_2 , the mixture was both plated on MA + Thr, Met, DAP, Bio, Thd, Glucose containing $10 \mu\text{g}$ trimethoprim/ml and diluted into L broth + Thd + DAP + 10^{-2} M citrate (1 ml into 9 ml) to allow growth for segregation and expression. After growth to about 2×10^8 cells/ml samples were plated on selective media and another 1 to 10 dilution was made into L broth + Thd + DAP + 10^{-2} M citrate. The plating, dilution, incubation and final plating were repeated once more. The frequencies of colonies appearing on selective media were 1.2×10^{-6} , 7.0×10^{-7} , 1.3×10^{-6} and 1.8×10^{-6} for the immediate plating and following growth of the first, second and third diluted mixtures. The percentages of thermosensitive Thy^- clones were 40, 29, 21 and 11 for the four platings. In addition, the trimethoprim-resistant colonies grew up after 3 days incubation for the first two platings whereas only 2 days incubation were required for the last two platings. Since about half of spontaneous Thy^- mutants are thermosensitive for their thymine requirement (i.e., they grow at 30°C . without thymine) and since transductant colonies should grow faster than colonies arising from spontaneous mutations occurring on the plates, the non-thermosensitive clones appearing from the last two platings were believed to represent successful *thyA57* transductants. One of these was designated $\times 1776$. Subsequently, it was discovered that $\times 1776$ as well as several other of these non-thermosensitive *thyA* clones were able to revert to Thy^+ at a very low frequency thus casting doubt on the belief that the *thyA* mutation in $\times 1776$ is the *thyA57* allele which may indeed be a composite of two mutations in the *thyA* gene, only one of which was introduced into $\times 1776$. $\times 1776$ is also less able to grow at 42°C . than $\times 1864$ and possesses at least one additional mutation that alters the structure of the outer membrane and contributes to bile sensitivity, phage resistance and the Con- recipient phenotype. This mutation designated *oms-2* is about 65 to 80 percent cotransducible with *thyA*.

CHART C. GENEALOGY OF $\times 1776$.

$\times 1276$	F ⁻ <i>ara-40 minA1 purE41 supE42 λ^- pdxC3 minB2 his-53 metC65 rpsL97 T3⁺ xyl-14 ilv-277 cycB2 cycA1</i>	
↓	X ⁺ 1487 with sel'n. for Ara ⁺ Str ^r to introduce <i>hsdR2</i> allele	
$\times 1488$	F ⁻ <i>minA1 purE41 supE42 λ^- pdxC3 minB2 his-53 metC65 rpsL97 T3⁺ xyl-14 ilv-277 cycB2 cycA1 hsdR2</i>	
↓	X ⁺ 602 with sel'n. for Xyl ⁺ Cyc ^r to eliminate <i>rpsL97</i> allele	
$\times 1678$	F ⁻ <i>minA1 purE41 supE42 λ^- pdxC3 minB2 his-53 metC65 T3⁺ ilv-277 cycB2 cycA1 hsdR2</i>	
↓	P1L4 ($\times 1656$) with T5 sel'n. to cotransduce in <i>dapD8</i> allele; with concomitant loss of <i>pdxC3</i>	
$\times 1697$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 λ^- minB2 his-53 metC65 T3⁺ ilv-277 cycB2 cycA1 hsdR2</i> (contains TS mutation linked to <i>dapD8</i> that prevents growth at 42°C . but not at 37°C .)	
↓	spont. sel'n. at 42°C . to eliminate TS defect	
$\times 1702$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 λ^- minB2 his-53 metC65 T3⁺ ilv-277 cycB2 cycA1 hsdR2</i>	
↓	Avir sel'n. to obtain <i>malT</i> derivative	
$\times 1777$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 λ^- minB2 his-53 metC65 T3⁺ malT43 ilv-277 cycB2 cycA1 hsdR2</i>	
↓	P1L4 ($\times 660$) with sel'n. for Mal ⁺ and Aro ⁻ to introduce <i>aroB15</i> allele	
$\times 1820$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 λ^- minB2 his-53 metC65 T3⁺ aroB15 ilv-277 cycB2 cycA1 hsdR2</i>	
↓	P1L4 ($\times 1825$) with sel'n. for Aro ⁺ to introduce $\Delta 29[\text{bioH-}asd]$ deletion	
$\times 1845$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 λ^- minB2 his-53 metC65 T3⁺ $\Delta 29[\text{bioH-}asd]$ ilv-277 cycB2 cycA1 hsdR2</i>	
↓	spont. sel'n. for resistance to $100 \mu\text{g}$ nalidixic acid/ml	
$\times 1846$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 λ^- minB2 his-53 nalA25 metC65 T3⁺ $\Delta 29[\text{bioH-}asd]$ ilv-277 cycB2 cycA1 hsdR2</i>	
↓	nitrous acid mutagenesis and sel'n. for anaerobic chlorate resistance on MacConkey-Gal agar accompanied by introduction of <i>oms-1</i> mutation	

CHART C.

GENEALOGY OF $\times 1776$ (continued).

5	$\times 1849$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 $\Delta 40$[gal-uvrB] λ^- minB2 his-53 nalA25 metC65 oms-1 T3⁺ $\Delta 29$[bioH-<i>asd</i>] ilv-277 <i>cycB2 cycA1 hsdR2</i></i>	5	
	↓	P1L4 ($\times 289$) with sel'n. for His ⁺ with concomitant change to Con ⁻ , bile salts sensitivity and TS phenotype		
10	$\times 1855$	F ⁻ <i>tonA53 dapD8 minA1 purE41 supE42 $\Delta 40$[gal-uvrB] λ^- minB2 rfb-2 nalA25 metC65 oms-1 T3⁺ $\Delta 29$[bioH-<i>asd</i>] ilv-277 <i>cycB2 cycA1 hsdR2</i></i>	10	
	↓	P1L4 ($\times 289$) with sel'n. for Pur ⁺		
15	$\times 1859$	F ⁻ <i>tonA53 dapD8 minA1 supE42 $\Delta 40$[gal-uvrB] λ^- minB2 rfb-2 nalA25 metC65 oms-1 T3⁺ $\Delta 29$[bioH-<i>asd</i>] ilv-277 <i>cycB2 cycA1 hsdR2</i></i>	15	
	↓	P1L4 ($\times 289$) with sel'n. for Ilv ⁺		
20	$\times 1864$	F ⁻ <i>tonA53 dapD8 minA1 supE42 $\Delta 40$[gal-uvrB] λ^- minB2 rfb-2 nalA25 metC65 oms-1 T3⁺ $\Delta 29$[bioH-<i>asd</i>] <i>cycB2 cycA1 hsdR2</i></i>	20	
	↓	P1L4 ($\times 559$) with trimethoprim sel'n. to introduce <i>thyA57</i> allele with presumed concomitant introduction or expression of an additional mutation affecting outer membrane structure		
	$\times 1776$	F ⁻ <i>tonA53 dapD8 minA1 supE42 $\Delta 40$[gal-uvrB] λ^- minB2 rfb-2 nalA25 oms-2 <i>thyA57*</i> metC65 oms-1 T3⁺ $\Delta 29$z[bioH-<i>asd</i>] <i>cycB2 cycA1 hsdR2</i></i>		
25	$\times 1849$ through to $\times 1776$ are phenotypically T3 sensitive. The designation <i>thyA57*</i> used in the $\times 1776$ genotype is to indicate that this <i>thyA</i> mutation which reverts may not have been derived from the non-reverting <i>thyA57</i> mutation in $\times 559$.			25
30	Construction of $\times 2076$. During the testing of $\times 1776$, it became apparent that both <i>thyA</i> ⁺ and bile salts resistant revertants were obtained at very low but measureable frequencies. In other studies it was learned that the <i>endA1</i> mutation increased transformability of strains 5 to 10 fold and that the combination <i>thyA deoA upp</i> precluded growth of strains on thymine and resulted in improved rates of thymine-less death. It was therefore decided to construct an improved derivative of $\times 1776$ designated $\times 2076$ (see Chart D).			30
35	The steps involved in constructing $\times 2076$ are straightforward. The removal of the <i>thyA57*</i> mutation with the introduction of the <i>lysA32</i> mutation was associated with some difficulty, however, since some of these cotransductants presumably became <i>oms-2</i> ⁺ and thereby somewhat bile salts resistant. Also some of these cotransductants that retained bile salts sensitivity became completely resistant to P1L4 thus precluding further use of P1 transduction for strain construction. For this reason, a <i>thy</i> ⁺ <i>lysA32</i> cotransductant that still exhibited sensitivity to P1 was selected and this strain ($\times 2065$) was transduced to <i>lysA</i> ⁺ <i>thyA57</i> to yield $\times 2067$. The <i>thyA57</i> mutation in this strain has not been observed to revert to <i>thyA</i> ⁺ .			35
40	The introduction of the <i>serA12</i> allele to permit cotransduction of <i>serA</i> ⁺ and <i>endA1</i> and of the <i>serB31</i> allele to permit introduction of <i>serB</i> ⁺ and $\Delta deoA$ utilizes the ampicillin-cycloserine enrichment technique following P1L4 transduction and a period of growth under permissive conditions to permit segregation and phenotypic expression.			40
45	<i>upp</i> mutations confer resistance to 5'-fluorouracil and therefore can be selected as spontaneous mutations with subsequent testing of mutants by standard techniques to verify that the resistance to 5'-fluoro-uracil is due to an <i>upp</i> mutation. The selection of spontaneous mutations for resistance to phage K3 which results in alteration of outer membrane protein 3a and a Con ⁻ recipient phenotype in matings with donors possessing F-type plasmids and for resistance to phage T4 which results in mutations in the <i>lpcA</i> or <i>lpcB</i> genes and confers bile salts sensitivity are easily accomplished. However, the fact that $\times 1776$ is already Con ⁻ and bile salts sensitive complicates the genetic and phenotypic analysis of strains with additional mutations affecting these properties. Although non-revertability of the bile sensitivity trait and decreased recipient ability compared to $\times 1776$ will be testable attributes of $\times 2076$, the complete resistance of this strain to transducing phages and the inability to use conjugational analyses will essentially preclude a genetic analysis to determine which genes have been rendered defective by mutational lesions.			45
50				50
55				55
60				60

CHART D.

GENEALOGY OF λ 2076.

5	x1776	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 thyA57* metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i>	5
	↓	P1L4 (λ 1753) with sel'n. for <i>thyA</i> ⁺	
	x2065	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 lysA32 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i>	10
	↓	P1L4 (λ 559) with sel'n. for <i>lysA</i> ⁺	
	x2067	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 thyA57 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i>	15
	↓	P1L4 (λ 573) with Amp-Cyc enrichment	
	x2068	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 thyA57 serA12 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i>	20
	↓	P1L4 (λ 1821) with sel'n. for <i>serA</i> ⁺	
	x2069	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 thyA57 endA1 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i>	25
	↓	P1L4 (λ 675) with Amp-Cyc enrichment	
	x2070	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 thyA57 endA1 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2 serB31</i>	30
	↓	P1L4 (λ 2056) with sel'n. for <i>serB</i> ⁺	
	x2071	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 oms-2 thyA57 endA1 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i> Δ deoA	35
	↓	spont. 5'-F-uracil resistance	
	x2073	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 upp oms-2 thyA57 endA1 metC65 oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i> Δ deoA	40
	↓	spont. sel'n. for K3 ^r	
	x2074	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 upp oms-2 thyA57 endA1 con metC65</i> <i>oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i> Δ deoA	45
	↓	spont. sel'n. for T4 ^r	
	x2076	F ⁻ <i>tonA53 dapD8 minA1 supE42</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>minB2</i> <i>rfb-2 nalA25 upp oms-2 thyA57 endA1 con metC65</i> <i>oms-1</i> Δ 29[<i>bioH-asd</i>] <i>cycB2 cycA1 hsdR2</i> Δ deoA <i>lpcA</i> or <i>lpcB</i> or <i>rfa</i>	50

Construction of λ 1972 and λ 1976. Although λ 1776 and λ 2076 are suitable safer hosts for use with plasmid cloning vectors in recombinant DNA molecule research, they are resistant to bacteriophage λ and are therefore not particularly useful in conjunction with λ -derived cloning vectors. For this reason and because the production of minicells is less important for experiments with λ cloning vectors, a series of strains was designed to facilitate use with these vectors as well as with plasmid cloning vectors. Chart E gives the genealogies of λ 1972 and λ 1976. The design and construction was based on findings and techniques described hereinabove. In addition to λ 1972 and λ 1976, strains λ 1961, λ 1963, λ 1966, λ 1968, λ 1969, λ 1970, λ 1973, λ 1974 and λ 1975 derived during their construction have utility for use with particular types of phage and plasmid cloning vectors.

CHART E.

GENEALOGIES OF λ 1972 AND λ 1976.

55	x1038	F ⁻ <i>lacY1 supE44 galK2 galT22</i> λ^- <i>metB1 hsdS3</i>	55
	↓	P1L4 (λ 289) with sel'n. for Gal ⁺	
	x1947	F ⁻ <i>lacY1 supE44</i> λ^- <i>metB1 hsdS3</i>	
	↓	spont. with anaerobic sel'n. for Gal ⁻ Chl ^r	

CHART E.

GENEALOGIES OF λ 1972 AND λ 1976 (continued).

	x1948	F ⁻ <i>lacY1 supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>metB1 hsdS3</i> spont. resistance to 50 μ g nalidixic acid/ml	
5	x1949	F ⁻ <i>lacY1 supE44</i> Δ 40[<i>gal-uvrB</i>] λ^- <i>nalA metB1 hsdS3</i> P1L4 (.559) with trimethoprim sel'n.	5
	x1950	F ⁻ <i>lacY1 supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>metB1 hsdS3</i> P1L4 (.289) with sel'n. for <i>metB</i> ⁺	
10	x1952	F ⁻ <i>lacY1 supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>hsdS3</i> P1L4 (.1702) with sel'n. for T5 ⁺	10
	x1953	F ⁻ <i>tonA53 dapD8 lacY1 supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>hsdS3</i> P1L4 (.573) with Amp.-Cyc. enrichment	
15	x1954	F ⁻ <i>tonA53 dapD8 lacY1 supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>serA12 hsdS3</i> P1L4 (.1821) with sel'n. for <i>serA</i> ⁺	15
	x1955	F ⁻ <i>tonA53 dapD8 lacY1 supE44</i> Δ [<i>gal-uvr</i>] λ^- <i>nalA</i> Δ thyA57 <i>endA1 hsdS3</i> P1L4 (.289) with sel'n. for <i>lacY</i> ⁺	
20	x1956	F ⁻ <i>tonA53 dapD8 supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>endA1 hsdS3</i> P1L4 (.2017) with Amp.-Cyc. enrichment	20
	x1957	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>endA1 hsdS3</i> P1L4 (.675) with Amp.-Cyc. enrichment	
25	x1958	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>endA1 hsdS3 serB31</i> P1L4 (.2056) with sel'n. for <i>serB</i> ⁺	25
	x1959	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> Δ thyA57 <i>endA1 hsdS3</i> Δ deoA P1L4 (.2055) with sel'n. for 5'-F-uracil resistance	
30	x1960	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA</i> <i>dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 hsdS3</i> Δ deoA P1L4 (.1091) with sel'n. for resistance to λ vir N N	30
35	x1961	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ</i> Δ [<i>gal-uvrB</i>] λ^- <i>nalA dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 hsdS3</i> Δ deoA P1L4 (.1525) with Amp.-Cyc. enrichment	35
	x1962	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- Δ trpE63 <i>nalA dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 hsdS3</i> Δ deoA P1L4 (.1087) with sel'n. for Trp ⁺	
40	x1963	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- <i>supF58 nalA</i> <i>dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 hsdS3</i> Δ deoA P1L4 (.1674) with Amp.-Cyc. enrichment	40
	x1964	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- Δ trpE63 <i>nalA dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 mtlA9 hsdS3</i> Δ deoA P1L4 (.1108) with Amp.-Cyc. enrichment	
45	x1965	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- Δ trpE63 <i>nalA dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 mtlA9 metE98</i> <i>hsdS3</i> Δ deoA P1L4 (.2058) with sel'n. for <i>met</i> ⁺	45
50	x1966	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- Δ trpE63 <i>nalA dapA</i> or <i>E upp</i> Δ thyA57 <i>endA1 mtlA9 polA</i> (CS) <i>hsdS3</i> Δ deoA P1L4 (.1717) with Amp.-Cyc. enrichment	50
55	x1967	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ supE44</i> Δ [<i>gal-uvrB</i>] λ^- Δ trpE63 <i>nalA dapA</i> or <i>E upp srl-2</i> Δ thyA57 <i>endA1 mtlA9 polA</i> (CS) <i>hsdS3</i> Δ deoA P1L4 (.1091) with sel'n. for resistance to λ vir N N	55
60	x1969	F ⁻ <i>tonA53 dapD8</i> Δ <i>lacZ</i> Δ [<i>gal-uvrB</i>] λ^- Δ trpE63 <i>nalA dapA</i> or <i>E upp srl-2</i> Δ thyA57 <i>endA1 mtlA9 polA</i> (CS) <i>hsdS3</i> Δ deoA spont.sel'n. for K3 ⁺	60

CHART E.

GENEALOGIES OF \times 1972 AND \times 1976 (continued).

5	\downarrow	\times 1970	F ⁻ <i>tonA53 dapD8 ΔlacZ Δ[gal-uvrB] λ^- ΔtrpE63 nalA</i> <i>dapA or E upp srl-2 ΔthyA57 endA1 con mt1A9</i> <i>polA(CS) hsdS3 ΔdeoA</i>	5
10	\downarrow	\times 1972	spont. sel'n. for T4 ^r F ⁻ <i>tonA53 dapD8 ΔlacZ Δ[gal-uvrB] λ^- ΔtrpE63 nalA dapA</i> <i>or E upp srl-2 ΔthyA57 endA1 con mt1A9 polA(CS)</i> <i>hsdS3 ΔdeoA lpcA or lpcB or rfa</i>	10
15	\downarrow	\times 1968	P1L4 (\times 1087) with sel'n. for <i>trp</i> ⁺ F ⁻ <i>tonA53 dapD8 ΔlacZ supE44 Δ[gal-uvrB] λ^- supF58</i> <i>nalA dapA or E upp srl-2 ΔthyA57 endA1 mt1A9</i> <i>polA(CS) hsdS3 ΔdeoA</i>	15
20	\downarrow	\times 1973	P1L4 (\times 1707) with sel'n. for <i>srl</i> ⁺ F ⁻ <i>tonA53 dapD8 ΔlacZ supE44 Δ[gal-uvrB] λ^- supF58</i> <i>nalA dapA or E upp recA1 ΔthyA57 endA1 mt1A9 polA(CS)</i> <i>hsdS3 ΔdeoA</i>	20
25	\downarrow	\times 1974	spont. sel'n. for K3 ^r F ⁻ <i>tonA53 dapD8 ΔlacZ supE44 Δ[gal-uvrB] λ^- supF58</i> <i>nalA dapA or E upp recA1 ΔthyA57 endA1 con mt1A9</i> <i>polA(CS) hsdS3 ΔdeoA</i>	25
30	\downarrow	\times 1975	spont. sel'n. for T4 ^r F ⁻ <i>tonA53 dapD8 ΔlacZ supE44 Δ[gal-uvrB] λ^- supF58</i> <i>nalA dapA or E upp recA1 ΔthyA57 endA1 con mt1A9</i> <i>polA(CS) hsdS3 ΔdeoA lpcA or lpcB or rfa</i>	30
	\downarrow	\times 1976	spont. sel'n. for T3 ^r T7 ^r F ⁻ <i>tonA53 dapD8 ΔlacZ supE44 Δ[gal-uvrB] λ^- supF58</i> <i>nalA dapA or E upp recA1 ΔthyA57 endA1 con mt1A9</i> <i>polA(CS) hsdS3 ΔdeoA lpcA and/or lpcB and/or rfa</i>	

A deposit of \times 1038 has been made with the American Type Culture Collection, Rockville, Maryland, U.S.A. and has been assigned ATCC No. 31246.

METHODS USED AND RESULTS OF TESTING GENOTYPIC AND PHENOTYPIC PROPERTIES OF MICROORGANISMS WITH SPECIAL REFERENCE TO \times 1776 AS AN EXAMPLE.

MATERIALS AND METHODS.

General. The media, bacteriophages and bacterial strains (see Table 1), and the methods for transduction, mutagenesis and mutant enrichment, conjugation, minicell production and growth were described hereinabove. Table 3 lists the strains possessing conjugative plasmids that were used to test the recipient ability of \times 1776 under various conditions and to investigate the mobilization and transmission of non-conjugative plasmid cloning vectors such as pSC101, pMB9 and pCR1 in biparental and triparental matings.

Survival. Ability of cells to give rise to colonies as a function of time under various non-permissive conditions were measured by plating appropriate dilutions on media that were optimal for the recovery and growth of \times 1776 or its plasmid-containing derivatives.

Labelling and isolation of DNA. Cells were labelled with [³H]thymidine using standard methods. Plasmid DNA was isolated by using the cleared lysate procedure and/or the ethidium bromide-CsCl procedure. Plasmid DNA from minicells was isolated and analysed by alkaline and neutral sucrose gradient centrifugation. Alkaline sucrose gradients were also used to evaluate breakdown of chromosomal DNA.

Determination of radioactivity. Samples containing radioactively labelled DNA were placed on Whatman (Trademark) 3 MM filters and the DNA was precipitated with trichloroacetic acid. Radioactivity was determined in a Beckman (Trademark) Model LS-230 liquid scintillation counter using a BBOT-toluene scintillation fluid in minivials.

Transformation. The method described by Lederberg and Cohen (1974) was initially used to transform strains with plasmid DNA although these methods are unsatisfactory for λ 1776 and other strains with mutations altering the outer membrane structure. A new method for transformation of such strains has therefore been developed as described hereinafter. pSC101 plasmid DNA was used to transform λ 1776 to yield λ 1876 which has been tested in comparison to λ 1776 to verify that the presence of a plasmid cloning vector does not alter the utility or safety properties of λ 1776. More limited tests have been performed with λ 1776 derivatives transformed with pMB9 DNA (λ 2042) and pCRI DNA (λ 2043).

Other Methods. Methods that are unique to a particular experiment are described in conjunction with that experiment. When not otherwise indicated incubations were at 37°C.

RESULTS

GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF STRAINS.

Phenotypes associated with mutations in λ 1776. The phenotypic properties of λ 1776 and the listing of mutations responsible for each trait are given in Table 4.

Stability of genotypic and phenotypic traits. Data on the reversion of various mutational markers in λ 1776 and λ 1876 are presented in Table 5. As expected those traits that are due to deletions and/or to two mutational lesions do not revert. Actually most of these traits have been checked for stability in some of λ 1776's ancestors (Chart C) and shown not to revert. In addition, λ 1776 has been tested for reversion following nitrosoguanidine and methyl methane sulfonate mutagenesis and no revertants were detected except Thy^+ revertants. Thus it is most likely that the Dap^- , Mal^- , Bio^- , Gal^- , Met^- , Thr^- and Glyc^- traits will not revert. The reversion of the *thyA* mutation was, however, quite unexpected, since it had been believed that the non-reverting *thyA57* allele had been successfully transduced into λ 1776.

Table 6 presents data on the frequency of alteration of several other phenotypic traits expressed by λ 1776 and λ 1876. The frequencies of *deoB* and *deoC* mutations that permit λ 1776 and λ 1876 to grow on media with 2 μg thymine/ml instead of with 40 μg /ml of either thymine or thymidine (Table 6) is about 1000 times higher than the frequency of such mutants that arise when selecting for Thy^+ revertants (see footnote to Table 5). As indicated later, these secondary mutations in λ 1776 to *deoB* or *deoC* do not adversely affect the rates of thymineless death or survival during passage through the rat intestine. Revertants able to grow at 42°C. are also readily obtainable (Table 6), although they are not detected when high densities of cells ($>5 \times 10^7$) are plated. In comparing these revertants with thermoresistant transductants (see later), it was noted that some of the transductants plate at 100% efficiency at 42°C. compared to 37°C. whereas for three revertants tested, plating efficiencies at 42°C. were 0.3 to 0.7% of those at 37°C. The revertants also grow at 37°C. but not at 42°C. on supplemented MA whereas the TS^+ transductants grow on supplemented MA at both 37° and 42°C. TS^+ revertants and some transductants retain bile salts sensitivity and are unable to plate on MacConkey agar. It is thus likely that the revertants are due to various secondary mutational events that suppress the original mutant phenotype and are not due to reversion at the original mutational site. It is now believed that the TS^+ phenotype is due to two mutations, *oms-1* and *oms-2*, the latter of which is cotransducible with *thyA*, and both of which influence outer membrane structure, bile salts sensitivity, etc.

Revertants that can plate on media with either bile salts or detergents appear at similar frequencies (Table 6). Several colony types appear on MacConkey agar and on L agar + bile salts and these can be correlated with different levels of resistance to detergents. It is thus likely that several types of mutations are responsible for the bile salts- and detergent-resistance phenotypes. Those revertants that plate with high efficiency and form large colonies on both MacConkey agar and L agar containing bile salts (0.37% or more) have numerous associated changes that in some respects compromise the safety of λ 1776 and λ 1876. Of some interest is the observation that these high-level bile salts resistant revertants plate with low efficiency (about 1%) on L agar + DAP, Thd at 42°C. Even though this property is like the behaviour of the TS^+ revertants, those TS^+ revertants so far tested retain bile salts sensitivity.

Verification of λ 1776 genotype. The genotype of λ 1776 was verified by using PIL4 transduction to select various transductant classes that could then be further tested. Table 7 presents the results of these transductions. Representative numbers

of transductant colonies were picked into BSG + DAP, restreaked on the medium used to select them and then single colonies were picked and streaked on various selective media. All transductants selected as Thr⁺, Mal⁺, Thr⁺ Mal⁺ or Glyc⁺ had the same properties and were Thr⁺, Mal⁺, Glyc⁺, λ⁺, T5⁺, Bio⁺, Met⁺, Gal⁺, Thy⁺, Dap⁻ and UV⁺. These results along with the inability to obtain Bio⁺ or Met⁺ transductants implied the existence in x1776 of two mutations giving the Met⁻ phenotype (*metC65* and $\Delta 29[bioH-*asd*]$) and two mutations giving the Bio⁻ phenotype ($\Delta 40[gal-*uvrB*]$ and $\Delta 29[bioH-*asd*]$). In corroboration, the Gal⁺ transductants remained Thr⁻, Met⁻, Dap⁻, Thy⁻, Mal⁻, Glyc⁻ and Bio⁻ but became UV⁺ as expected and formed mucoid colonies under appropriate conditions which is indicative of ability to produce colanic acid. The Thy⁺ transductants also had the expected properties and retained the phenotypes associated with all other mutations except that between 65 and 85% lost the thermosensitive property and some of these were shown to plate at 100% efficiency at 42°C. on both L agar and supplemented minimal agar. It is therefore evident that a mutation necessary for the TS phenotype is closely linked to *thyA*.

The so-called "Dap⁺ transductants" (Table 7) are an enigma since they are in fact Dap⁻. They remain Thr⁻, Mal⁻, Bio⁻, Glyc⁻, Met⁻, Thy⁻, Gal⁻ and UV⁺. When these transductants are grown in L broth containing DAP, Bio and Thd and plated directly on Penassay agar lacking DAP, some colonies will grow up provided that the Penassay agar contains NaCl. If these cultures are diluted 10 fold in BSG + DAP and then plated on Penassay agar lacking DAP, colonies will also appear if NaCl is included in the agar medium. x1776 cultures grown and plated in the same ways do not form colonies on DAP-deficient plates. If these transductant cultures are first diluted 1000 fold in BSG and then plated on Penassay agar with or without DAP, colonies are only formed on the medium containing DAP. These "DAP⁺ transductants" of x1776 form faster-growing colonies than x1776 on MA plates containing DAP, although after 3 days incubation at 37°C. the colonies are indistinguishable in size. "Dap⁺ transductants" may therefore represent phenotypes that require lower concentrations of DAP for growth and are thus able to derive sufficient amounts of DAP to sustain growth from the DAP contained in either the L broth + DAP growth medium or the BSG + DAP diluent that is added to the medium at the time of plating. It should be noted that these "Dap⁺" types grow slower than x1776 in broth media and have not been observed to occur by mutation during reversion tests. In a further attempt to understand the nature of these "Dap⁺ transductants", they have been transduced to Thr⁺ to eliminate the $\Delta 29[bioH-*asd*]$ mutation and were then shown to still possess the *dapD8* mutation.

P1L4 was propagated on x1925, a bile salts resistant revertant of x1776 (Table 6) in order to further analyse some of the mutations in x1776. Various strains with *galK* and *galT* mutations were transduced to see if Gal⁺ transductants were formed. None were at frequencies that could have been up to 10⁴ times lower than the frequencies of Leu⁺ transductants selected in the same recipient. Thus the $\Delta 40[gal-*uvrB*]$ mutation deletes most, if not all, of the *gal* operon. P1L4 (x1925) was also used to transduce x1753 to LysA⁺ and a number of *thyA* cotransductants were selected to determine whether the *thyA* mutation did or did not revert when returned to a pure W1485 derived strain. Several of these *thyA* strains reverted to Thy⁺ at frequencies of about 10⁻⁹. P1L4 (x559) was also used to transduce x1753 to LysA⁺ *thyA57* and several of these transductants failed to yield detectable ThyA⁺ revertants. It would thus appear that either the *thyA* allele in x1776 represents a new allele arising by mutation and not by transduction from x559 or the *thyA57* mutation in x559 is really two separable mutations in the *thyA* gene with only one of them having been transduced into x1864 to yield x1776.

P1L4 transduction has also been used in an attempt to determine the genetic basis for the bile salts sensitivity trait that appeared concomitantly with the TS defect during transduction of x1849 to His⁺ with P1L4 (x289) to yield x1855 (Chart C). When P1L4 (x289) is used to transduce x1776 to ThyA⁺, 65 to 85% of the transductants become thermo-resistant and regain partial but not complete resistance to bile salts. Gal⁺ transductants of x1776 obtained by using P1L4 (x289) retain bile salts sensitivity and fail to plate on MacConkey agar. These transductants also retain their temperature-sensitive phenotype but become UV resistant and regain the ability to synthesize colanic acid. It therefore appears that the $\Delta 40[gal-*uvrB*]$ mutation is not necessary for expression of either bile salts sensitivity or temperature sensitivity. When x1849 is transduced to His⁺ with P1L4 grown on x289, x1038 or derivatives of the C600 and K-12-112 sublines, about 30% of the His⁺ transductants become bile salts sensitive and temperature

sensitive. Since none of the His⁺ transductants of \times 1846 or any of its ancestors becomes bile salts sensitive, it is inferred that an additional mutation other than the $\Delta 40[gal-uvrB]$ arose during the derivation of \times 1849 from \times 1846 which permits the expression of a mutation that is linked to *his* and is presumably present in many K—12 sublines. In accord with this idea is the fact that selection of bile salts resistant transductants of \times 1776 following transduction with P1L4 grown on \times 403, a *his* mutant derived from \times 289 (Table 1), results in a high yield of such transductants none of which become His⁻. These transductants, however, like the bile salts resistant revertants, are partially temperature resistant giving a 10⁻² plating efficiency on L agar at 42°C. They also retain all of the other known mutational lesions of \times 1776 so this mutation designated *oms-1* that permits the expression of the *his*-linked mutation in \times 1776 but which in the wild-type state prevents the expression of this *his*-linked mutation in various K—12 strains is not closely linked to any \times 1776 genetic marker. Based on cotransduction frequency data and phage sensitivity patterns it is believed that the *his*-linked mutation is in either the *rfbA* or *rfbB* locus. In another type of experiment in which an Hfr donor that transfers its chromosome clockwise commencing near the *metC* gene (minute 64) and which transfers the *thyA-lysA* region (minutes 60 to 61) last was mated with \times 1776, completely bile salts resistant transconjugants were formed early in the mating. These transconjugants were partially temperature resistant. All these results; imply that the gene designated *oms-1* that is present in \times 1849, is located in the 64 to 72 minute interval of the *E. coli* chromosome, and in conjunction with the *rfb-2* allele confers sensitivity to bile salts, detergents, drugs, antibiotics, etc., resistance to phage and contributes to inability to grow at 42°C. These results also imply the existence of another gene *oms-2* which first appeared in \times 1776, is located at about minute 60.2 on the *E. coli* chromosome linked to *thyA* and which augments the thermosensitivity and bile salts sensitivity of \times 1776. The inability of P1L4 transducing phage to propagate on \times 1776 makes a complete genetic analysis of the basis and interactions of the *rfb-2*, *oms-1* and *oms-2* mutations very difficult.

In testing for the restrictionless phenotype of \times 1776, it was first determined that phages 434, ϕ 12, P1L4, 6SR, FP3, Br10, BF23 and ϕ H were not restricted by the K—12 system. λ and 21 could not be tested on \times 1776, of course because of the $\Delta 29[bioH-asd]$ mutation nor could T1 and ϕ 80 because of the *tonA53* mutation. It was therefore decided to use the Thr⁺ transductants obtained from \times 1776 and λ vir. The results obtained indicate that these \times 1776 Thr⁺ transductants are restrictionless. However, the \times 1776 Thr⁺ transductants gave a uniform 3-fold reduction in λ vir plating efficiencies. It should also be noted that growth of host bacteria in L broth (which contains glucose) and plating on media lacking maltose results in a 90-fold reduction in plating efficiencies of λ vir on the \times 1776 Thr⁺ transductants compared to plating on \times 289 for the same conditions. Growth of these host strains in a modified L broth medium containing maltose and plating on medium without maltose resulted in a 5-fold reduction. These effects are specific for the \times 1776 derivatives since equal λ vir plating efficiencies were obtained for all combinations of media with or without maltose for λ vir plating on \times 289 and \times 1038. The restrictionless phenotype of \times 1776 has also been confirmed by transformation with plasmid DNA from \times 289 and \times 1038 derivatives.

The presence of the *supE42* mutation was also investigated using the \times 1776 Thr⁺ transductants. λ cI857 N7 N213 was found to give an efficiency of plating of about 10⁻¹ on most of these strains when maltose was present in all media. When 0.1% glucose replaced 0.3% maltose in all media, no λ cI857 N7 N213 plaques were observed. These results also show that the \times 1776 Thr⁺ transductants are more dependent on maltose for λ growth but less above to support λ reproduction than are "wild-type" K—12 strains. The poor growth of the double N λ mutant, however, might imply that the *supE42* allele in the \times 1776 Thr⁺ transductants has been modified so as to only weakly suppress the double N λ mutant. To rule out this explanation, the pLM2 plasmid which has amber mutations in the *bla* and *tet* genes was introduced into \times 1776. Resistance to both ampicillin and tetracycline were expressed normally thus indicating the presence of an unaltered *supE42* allele.

Growth properties. The efficiencies of plating of \times 1776 were tested on a variety of media in the presence and absence of cycloserine and nalidixic acid as a means to determine the best media for its growth and recovery from mixed populations of microorganisms and to verify certain expected phenotypes. (Similar, although more limited, tests were done with most of \times 1776's ancestral parents and \times 1876.) \times 1776 gives 100% plating efficiencies on appropriately supplemented L agar,

Penassay agar and Minimal Agar containing glucose with or without Casamino acids. Plating efficiencies of 90 and 80 percent were observed on appropriately supplemented EMB and Brain Heart Infusion Agars, respectively. The plating efficiency on Minimal Agar containing Casamino acids with no added carbon source was 10^{-2} but was less than 10^{-6} when glycerol was added. This latter result is expected since the $\Delta 29[bioH-asd]$ mutation deletes the gene for the aerobic glycerol phosphate dehydrogenase and thus glycerol phosphate should accumulate in cells and cause glycerol stasis. $\times 1776$ also gives a 10^{-3} plating efficiency on Tryptone (1%) Agar containing DAP, Thd and Bio.

When high densities of $\times 1776$ were plated on those media giving very low plating efficiencies, mutants and/or revertants were sometimes obtained. Such types were purified on the same selective media and then representative types were subjected to numerous tests. Then tests included verification of relevant phenotypic properties (nutritional requirements; plating efficiencies; sensitivity to phages, antibiotics, detergents, etc.; rates of DAP-less and thymineless death; survival during passage through rats; etc.). All of these isolates had the same nutritional requirements as $\times 1776$ and grew at the same or usually at slower rates than $\times 1776$ in liquid media. With the exception of some of the bile salts resistant mutants, they possessed the same phenotypic traits and exhibited the same or faster rates of DAP-less and thymineless death as $\times 1776$. Certain of these isolates did plate with altered efficiencies on certain media, especially on the medium on which selected.

Table 8 gives plating efficiencies for $\times 1776$ on various media with different concentrations of nalidixic acid and/or cycloserine. EMB agar containing 75 μg nalidixic acid/ml was selected for recovery of strains from the mixed flora present in the rat intestine. It should be noted that yeast extract was omitted from EMB agar used to recover strains in rat feeding tests since it was desirable to make the medium as sparse as possible for the resident flora. Pdx and Ade were added to this medium since the former is required by $\times 1841$ ($\times 1488 \text{ Nal}^r$) and the latter by many of $\times 1776$'s ancestors (see Chart C). Except in EMB agar, nalidixic acid was generally used at 25 $\mu\text{g}/\text{ml}$. Actually the minimal inhibitory concentration (MIC) of nalidixic acid for Nal^r strains in EMB agar is double the MIC in L agar. Regular EMB agar (containing yeast extract, DAP and Thd) with 25 μg nalidixic acid/ml and sometimes with 10 to 15 μg cycloserine/ml is routinely used for transformation of $\times 1776$ to preclude inadvertent and improbable transformation of a contaminant.

After doing a number of preliminary studies on the growth of $\times 1776$ and $\times 1876$ in complex liquid media it was decided that supplemented L broth gave better growth rates and cell yields than did either Penassay broth or Brain Heart Infusion broth. Thus $\times 1776$ and $\times 1876$ have generation times of 50 to 60 minutes in L broth + DAP + Thd, 85 to 95 minutes in ML + CAA + DAP + Bio + Thd + Glucose and 160 to 180 minutes in ML + Thr + Met + DAP + Bio + Thd + Glucose. $\times 1841$ has generation times of about 42, 70 and 150 minutes in these three media. It is evident that the growth rates of $\times 1776$ and $\times 1876$ have decreased slightly over those exhibited by $\times 1841$, the Nal^r derivative of their ancestor $\times 1488$. More recently more rapid rates of growth for $\times 1776$ and $\times 1876$ than indicated have been measured. Indeed, $\times 1776$ can grow in supplemented ML with a generation time of 130 min. We believe that this more rapid growth is due to the greater awareness of the extreme sensitivity of $\times 1776$ and $\times 1876$ to ionic detergents and the consequent more meticulous care in washing and rinsing glassware. $\times 1776$ and $\times 1876$ seldom reach viable titers in excess of $5 \text{ to } 8 \times 10^8/\text{ml}$. The reason for this is unknown but it is unlikely to be due to either exhaustion of nutrients or accumulation of toxic byproducts since when a culture at approximately 6×10^8 cells/ml is sedimented and then suspended in fresh medium no further increase in cell number is observed and the supernatant fluid from such a culture will permit regrowth of $\times 1776$ cells to a titer of $5 \text{ to } 8 \times 10^8/\text{ml}$.

Effect of temperature on survival and plasmid curing. When $\times 1776$ is grown in L broth + DAP + Thd to log phase, suspended in BSG or L broth + DAP + Thd and then incubated at 43°C ., exponential rates of loss in colony-forming ability are observed during the first 6 to 9 hours of incubation. Survival decreases 55% per hr in L broth and 84% per hr in BSG. It has also been observed that during 20 hours of growth in L broth or Penassay broth (+ DAP and Thd) at 42°C ., pSC101-containing derivatives of $\times 1846$ and $\times 1849$, but not of $\times 1841$ ($\times 1488 \text{ Nal}^r$), lose pSC101 in 19 and 32 percent of the cells, respectively. This "curing" during incubation at 42°C . it therefore a property of the cells and not of the plasmid. Although $\times 1876$ will not grow at 42°C ., it will grow slowly at 41°C . and 3.4% of the

cells growing overnight at this temperature lose pSC101. This property could be useful for certain experiments. pSC101 is completely stable in all four strains grown at 37°C., however, since loss of tetracycline resistance has not been observed in over 4000 clones tested by replica plating.

Resistance to bacteriophages. The responses of λ 1776, its ancestors and derivatives to various *E. coli* phages are presented in Table 10. These results were obtained by the cross streak method which can be somewhat insensitive for detecting either low levels of sensitivity or partial resistance. For example, phage 434 only gives a 10^{-3} efficiency of plating on λ 1776 compared to λ 289 although by the cross streak method it appears that λ 1776 is quite sensitive to 434. In terms of sensitivity to P1L4, variations in resistance during the derivation of λ 1776 from λ 1488 have been noted (Chart C). This was most apparent in terms of the large reduction in the efficiency of plating of P1L4 that accompanied the introduction of the *his*⁺ and bile salts sensitivity (presumably *rfaA* or *rfaB*; see later) markers in going from λ 1849 to λ 1855 and the gradual decrease in P1L4 (λ 289) transduction frequencies during the derivation of λ 1776 (Table 11). It should be noted that P1L4 efficiencies of plating of lower than 10^{-10} on λ 1776 were observed by use of both L media and P1 minimal media. A number of experiments have been conducted to evaluate the basis for the ability of P1L4 to transduce but not plaque on λ 1776. Using standard methodology along with anti-P1 serum, it has been observed that only 5% as much P1 infects λ 1776 as infects λ 289 during a 30 min adsorption period, that the latent period in λ 1776 is twice as long as in λ 289 and the mean burst sizes are the same in both strains. Additional evidence that the resistance of λ 1776 to P1L4 infection is due to defects in P1 infection and not in P1 propagation was obtained from studies on phage production following thermoinduction of P1*cmI* *clr100* lysogens of λ 1776 and λ 289. With both λ 289 and λ 1776 lysogens, the numbers of plaque-forming units and transducing phages specifying chloramphenicol resistance were the same.

It is worth noting that the bile salts resistant revertants of λ 1776 and λ 1876 (λ 1925 and λ 1928) regain sensitivity to phages P1L4, D108, ϕ W, P ϕ 60 and C21 and resistance to ϕ 12 as displayed by λ 1849 (Table 10). It is therefore evident that the change in the bacterial cell surface associated with bile salts sensitivity also affects the ability of numerous phages to interact with that cell surface.

Taken collectively, these studies on resistance of λ 1776 to various phages indicate that λ 1776 is completely resistant to the specialized transducing phages λ 1, 21 and ϕ 80, is probably completely resistant to Mu, D108 and T1 which are capable of low frequencies of generalized transduction, is partially resistant to the specialized transducing phage 434 and is partially resistant to the generalized transducing phage P1. Although these changes are likely to reduce the probability of potential transductional gene transfer from λ 1776 in nature, it is also evident that the cell surface changes in λ 1776 now endow it with sensitivity to some known phages (Table 10) and probably to unknown phages which may be capable of specialized or generalized transduction.

Response to antibiotics, mutagens, drugs, detergents and bile salts. Table 12 lists the minimal inhibitory concentration (MIC) of numerous antibiotics, mutagens, drugs, detergents and bile salts for λ 289, λ 1841 (λ 1488 NaI⁺), λ 1776 and λ 1876 and one bile salts resistant derivative of λ 1776 (λ 1925; see Table 6). These data indicate that λ 1776 and λ 1876 are more sensitive to almost all tested compounds than their ancestors. Exceptions to this general rule are the increased resistance to nalidixic acid (due to *nalA25* mutation), trimethoprim (due to *thyA57*^{*} mutation) and cycloserine (due to *cycA1* and *cycB2* mutations) and for λ 1876 to tetracycline (due to the pSC101 plasmid). In this last regard, it should be noted that λ 1876's MIC for tetracycline (50 μ g/ml) is lower than the MIC for tetracycline needed for other "normal" strains harboring pSC101 (100 to 200 μ g/ml). Indeed, λ 1876 does not plate with 100% efficiency on agar medium containing more than 12.5 μ g tetracycline/ml whereas λ 1841 and λ 1846 derivatives containing pSC101 will plate with 100% efficiencies on agar medium containing 50 or even 100 μ g tetracycline/ml. It is thus likely that the introduction into λ 1776 of plasmid cloning vectors that specify resistance to other antibiotics will result in strains that express lower levels of antibiotic resistance than would "normal" strains of *E. coli* K-12.

The increased sensitivities of λ 1776 and λ 1876 to chloramphenicol should reduce the quantities of this drug needed to cause amplification of ColEI-derived plasmid cloning vectors. The extreme sensitivity of these strains to rifampicin should also be useful in studies on chimeric plasmid directed RNA synthesis in minicells.

The bile salts resistance derivative $\times 1925$ regains complete resistance to sodium dodecyl sulfate, Sarkosyl (a surface active, N-acylated sarcosine), deoxycholate, bile salts and rifampin, partial resistance to streptomycin, spectinomycin and kanamycin and is unchanged with regard to its increased sensitivity to chloramphenicol, tetracycline and mitomycin C when compared to the responses of $\times 289$, $\times 1841$ and $\times 1776$ (Table 12). It is thus likely that the mutations conferring sensitivity to bile salts are also responsible for the increased sensitivity of $\times 1776$ to most, if not all, of these other compounds.

In kinetic experiments, $\times 1776$ is rapidly killed by either 0.15% bile salts or 0.02% sodium dodecyl sulfate whereas $\times 289$ grows well in the combined presence of 0.15% bile salts and 0.4% sodium dodecyl sulfate. In other experiments, it has been found that $\times 289$ grows normally in L broth containing either 0.75% bile salts or 1% sodium dodecyl sulfate. $\times 1876$ shows the same rates of killings by bile salts and sodium dodecyl sulfate as found for $\times 1776$. Increasing the bile salts concentration above 0.15% does not accelerate the rates of killings of $\times 1776$ and $\times 1876$ whereas use of sodium dodecyl sulfate at 0.1% or above gives the maximum rate of killing observed for bile salts. The extreme sensitivity of $\times 1776$ to detergents should facilitate its use for plasmid DNA isolation and the sensitivity to bile salts should reduce its survival in the intestinal tract of animals. The extreme sensitivity of $\times 1776$ to ionic detergents can, however, complicate transformation experiments in which the DNA is obtained from cells by ionic detergent facilitated lysis. It is therefore very important to carefully dialyze the DNA to remove traces of ionic detergent or to use non-ionic detergents for DNA isolation since CaCl_2 -treated, cold-incubated, heat-shocked $\times 1776$ cells are rapidly killed by very low concentrations of ionic detergents.

Basis for assignment of one mutation conferring bile salts sensitivity to $rfbA$ or $rfbB$ locus. In *E. coli* K-12, the structure of the LPS has recently been characterized as [lipid A, $(\text{P})_n$, ketodeoxyoctanate]-[heptose]-[(glucose) $_1$]-[(glucose) $_2$ -(galactose) $_2$ -rhamnose]. The removal of galactose and consequently the rhamnose, which is due to *galE* or *galU* mutations, permits sensitivity to phage C21 which can infect $\times 1849$ and the bile salts resistant derivatives, $\times 1925$ and $\times 1928$, but not $\times 1776$ and $\times 1876$ (Table 10). Phage C21 infection requires the heptose-(glucose) $_1$ structure but is independent of the terminal two glucose moieties that are added in the form of UDP-glucose whose synthesis is regulated by the *galU* gene. Furthermore, since the Gal^+ transductants of $\times 1776$ (Table 7) can produce colanic acid, the bile salts sensitivity mutation in $\times 1776$ cannot block colanic acid synthesis and cannot therefore be in *galU*. The four glucose moieties attached to heptose to the LPS are added as TDP-glucose whose synthesis is controlled by the *rfa* and *rfa* loci. A mutation in either gene would therefore confer resistance to C21. Mutations in the *lpcA*, *lpcB* and *rfa* genes affect the $(\text{P})_n$ and heptose in the LPS core, confer increased sensitivity to antibiotics and resistance to phage T4. These mutations also confer resistance to P1 and to bile salts, detergents, etc. Since $\times 1776$ remains sensitive to T4, T7 and to some of the other rough-specific phages (FP3, BR10, SSR) and is only partially resistant to P1, mutations in *lpcA*, *lpcB* and *rfa* genes can reasonably be excluded as being responsible for $\times 1776$'s phenotype. Mutations in *envA* and *envB* can also be excluded since they are associated with anomalous cell division and unusual cell shapes that are not characteristic of $\times 1776$. It is therefore inferred that it is most likely that one of the mutations conferring bile salts sensitivity, which first appeared in $\times 1855$, is located in either the *rfa* or *rfa* gene which would be about 30% cotransducible with the *his* operon. It should be recalled that the data presented strongly suggest that this supposed *rfa* allele is present but not expressed in $\times 289$ and other K-12 sublines and that its expression in $\times 1855$ is due to the presence of another mutation designated *oms-1* which arose in $\times 1849$.

Sensitivity to UV and fluorescent light. In that the $\Delta 40[\text{gal-uvrB}]$ mutation deletes one of the genes specifying the endonuclease needed to make incisions in DNA adjacent to pyrimidine dimers (*uvrB*) and the gene for the photoreactivating enzyme (*phr*), it would be expected that $\times 1776$ and $\times 1876$ would be extremely sensitive to UV irradiation and would be unable to repair UV-induced dimers when illuminated with 365 nm light. These predictions have been experimentally confirmed by measurement of survival as a function of UV exposure dose and by illumination of cells with black light fluorescent light. The sensitivity of $\times 1846$ and $\times 1776$ to fluorescent light has also been measured to determine whether work with $\times 1776$ should be conducted in laboratories with either subdued or yellow lights. Cells were suspended in BSG + DAP + Thd and illuminated at room temperature

in closed wettable plastic tissue culture dishes with two parallel 15 watt cool white fluorescent tubes (Sylvania (Trademark) F15T—CW) held in a standard desk lamp 10 cm above the cultures. After 48 hr. \times_{1846} had a survival of 6% and \times_{1776} of 0.07%. The increased sensitivity of \times_{1776} compared to \times_{1846} is most likely accounted for by the small amounts of UV wavelengths that pass through the glass of the fluorescent tubes and the plastic lids of the cell culture dishes that contain the cells and also to the fact that \times_{1776} dies somewhat more rapidly than "wild-type" strains when starved in BSG at room temperature.

SURVIVAL OF STRAINS.

Dap-less death. The rates of DAP-less death for \times_{1776} and \times_{1876} have been examined many times under numerous conditions. Dap-less death occurs at reasonable rates when conditions are favorable for the cells to carry out macromolecular synthesis as occurs in L broth + Thd and in ML + Casamino acids + Bio, Thd, Glc. However, in supplemented ML lacking both DAP and lysine there is little or no DAP-less death with the loss of colony forming units being similar to what is observed for suspension of \times_{1776} in BSG. When lysine is added to ML, protein synthesis becomes possible and DAP-less death ensues but at slower rates than observed in the richer media. DAP-less death in all cases was accompanied by defective cell wall biosynthesis as visualized in the light microscope and by lysis as revealed by optical density measurements.

In some of the early experiments on DAP-less death, the effects of the addition of nalidixic acid and/or cycloserine at various concentrations to the liquid media as well as to various plating media were investigated. Based on all these and other studies it is recommended that nalidixic acid be used at no more than 25 $\mu\text{g}/\text{ml}$ in L broth and L agar when monitoring the survival of \times_{1776} and \times_{1876} , although up to 75 $\mu\text{g}/\text{ml}$ can be tolerated in EMB agar. Cycloserine can also be added to these media at concentrations up to 10 $\mu\text{g}/\text{ml}$ with maximum recovery of viable cells.

During the genetic construction of \times_{1776} and prior to the introduction of the $\Delta 40[\text{gal-uvrB}]$ mutation to block colanic acid biosynthesis, it was observed that the rate of DAP-less death was dependent on the NaCl concentration in L broth. It was experimentally determined that the presence of NaCl in L broth markedly decreases the rate of DAP-less death for \times_{1846} (which is able to produce colanic acid), but has less effect on the behaviour of \times_{1849} and displays no effect on the survival rate of \times_{1776} . In numerous experiments with \times_{1776} and \times_{1876} using both exponentially-growing and stationary-phase inocula and in which the initial density was varied from 10^6 to 10^{10} cells/ml, no significant differences in the initial rates of DAP-less death dependent on the presence or absence of NaCl in the medium have been observed. Since NaCl does confer a slight but reproducible protective effect on \times_{1849} , one or more of the genetic changes in going from \times_{1849} to \times_{1776} (Chart C) has abolished this effect of NaCl in diminishing the rate of DAP-less death. It has been found, however, that the ability of \times_{1776} and \times_{1876} cells which survive 6 to 10 hours of DAP starvation to grow slowly during the next 60 to 90 hours in L broth lacking DAP seems to be dependent on (or at least facilitated by) the presence of NaCl in the L broth. In other words, in L broth lacking NaCl \times_{1776} and \times_{1876} cells die completely whereas in the regular L broth which contains NaCl the slow regrowth of surviving cells is sometimes observed. It would thus seem logical to suspect that NaCl may facilitate the scavenging of DAP released by lysing cells. In this regard, it should be recalled that the "Dap⁺ transductants" (Table 7) are also unable to form colonies on L agar lacking both DAP and NaCl even when plated from the BSG + DAP diluent. Since Mg^{++} , Ca^{++} and K^{+} can substitute for Na^{+} in stimulating colanic acid synthesis and in permitting long-term survival of Dap⁻ strains (Pereira and Curtiss, unpublished), it is likely that \times_{1776} and \times_{1876} would survive less well in natural environments with low concentrations of cations.

The rates of DAP-less death have also been measured for inocula of different densities using log-phase and stationary-phase cultures, respectively. The fact that cells from log-phase cultures die more rapidly and to a greater extent than cells from stationary-phase cultures supports the conclusion that the rate and extent of DAP-less death increases as the metabolic growth potential of the cells increases. This conclusion is also supported by the observation that DAP-less death is very inefficient when very high cell densities are inoculated into the L broth lacking DAP.

In a number of experiments, it was observed that $\times 1776$ and $\times 1876$ whether under permissive or non-permissive conditions were adversely affected by the presence of more robust bacterial strains including a great diversity of laboratory contaminants such as strains of *Pseudomonas*, *Staphylococcus* and *Serratia*. The conclusion from these observations as well as from reconstruction experiments is that $\times 1776$ and $\times 1876$ are poorly able to compete with other "wild-type" microorganisms and thus are less able to survive and indeed die at faster rates in the presence of other microorganisms than in their absence. This finding should make it even less likely that $\times 1776$ could survive in nature should it inadvertently escape its carefully defined "laboratory" environment.

Since $\times 1776$ and $\times 1876$ are sensitive to bile salts and ionic detergents, their effects on DAP-less death were checked. Differences, although slight, were noted with sodium dodecyl sulfate increasing slightly and bile salts decreasing slightly the rates of DAP-less death. It has also been noted that the addition of ampicillin (100 $\mu\text{g/ml}$) and/or cycloserine (100 $\mu\text{g/ml}$) to $\times 1776$ cultures in DAP-deficient media accelerates the rates of death over that observed with DAP starvation alone.

This observation has therefore contributed to the development of an efficient method combining DAP-less and thymineless death with the addition of cycloserine and ampicillin as a very efficient means to enrich for mutant derivatives of $\times 1776$ as described hereinafter.

The rates of DAP-less death for three bile salts resistant derivatives from $\times 1776$ have been measured. $\times 1925$ (Table 6) and $\times 1951$ appear to be complete revertants to bile salts resistance in that they have properties similar to those of $\times 1849$. $\times 1926$, on the other hand, is only a partial revertant since it does not plate with high efficiency on L agar + 0.15% bile salts (Table 6). The rates and extents of DAP-less death of these bile salts resistant revertants were similar to those found for $\times 1776$ and $\times 1876$ although substantially decreased rates of DAP-less death have been noted on one or two occasions.

Thymineless death. $\times 1776$ and $\times 1876$ do not undergo thymineless death in L broth (as expected since they grow well in L broth without Thy or Thd) but did in ML and in ML containing Casamino acids. In both of these synthetic media, when cells surviving 20 hours starvation were grown under permissive conditions and then retested for thymineless death, the same rates of thymineless death were observed. It was also observed that prolonged starvation leads to slow regrowth of cells and a high percentage of the cells present at 72 or 96 hours have *deoB* or *deoC* mutations since they grow well on supplemented MA with 2 μg thymine/ml. Thymineless death does not occur when very high cell densities are used and density rather than growth phase of the culture at the inception of starvation is the more important factor in governing the rate and extent of thymineless death. Rate of growth is also important since thymineless death is usually more extensive in ML containing Casamino acids than in ML without Casamino acids.

Combined DAP-less and thymineless death. The combined effects of starvation for both DAP and thymidine in L broth, ML + CAA, Bio, Glc and ML + Thr, Met, Lys, Bio, Glc for $\times 1776$ and $\times 1876$ have been measured. Both the rates and final levels of survival were similar to those obtained for DAP or thymine starvation alone in the respective media. Thus the two types of starvation do not act synergistically. However, slow regrowth of cultures was never observed to occur in either ML medium even when incubations were continued for more than 100 hours.

DNA degradation during DAP-less and/or thymineless death. Since thymineless death results in single-strand breaks in DNA and should thus lead to DNA degradation, the rate of solubilization of [^3H]thymidine labelled DNA in $\times 1776$ and $\times 1876$ undergoing DAP-less and/or thymineless death was examined. More DNA is solubilized during DAP-less death (with or without simultaneous starvation for thymidine) than during thymineless death. This is presumably due to the liberation of both DNA and nucleases during DAP-less death with the consequence that the liberated DNA is rapidly degraded in the culture medium.

Prelabelled $\times 1776$ and $\times 1876$ DNA were analysed on alkaline sucrose gradients during thymineless death in ML + Casamino acids, DAP, Bio, Glc medium. There was no appreciable decrease in single-strand molecular weights accompanying the decrease in total acid-insoluble material and it thus appears that DNA degradation in $\times 1776$ and $\times 1876$ is an all or none response for each cell.

Survival in non-growth media. The survivals of $\times 1776$ and $\times 1876$ were measured under a variety of conditions that would not permit growth. The survival data for

x289, x1776 and x1876 in BSG, tap water and deionized water at room temperature were measured. Although death is slow in these media, as it is in ML lacking DAP and lysine, the x1776 and x1876 cells surviving after 8 days exhibited a two-fold greater sensitivity to sodium dodecyl sulfate, sarkosyl and bile salts than the original x1776 and x1876 cultures. On the other hand, the sensitivity of x289 to these compounds did not change during the starvation time. It has also been observed that aeration of x1776 and x1876 cells suspended in water, but not in BSG, accelerates their rates of death compared to x289.

When x1776 and x1876 were suspended in BSG or L broth + DAP + Thd and stored at 4°C., there was no detectable loss in viability over a period of two weeks. x1776 and x1876 cells were also suspended in 1% peptone-5% glycerol (containing DAP and thymidine) and two ml amounts placed in screw cap Wasserman tubes to determine the effects of rapid freezing and thawing. Freezing of x1776 and x1876 resulted in about a 50% loss in viability per freeze-thaw cycle whereas x289 exhibited a 30% loss in viability per cycle. There thus appears to be no difficulty in keeping x1776 and x1876 under non-physiological conditions that are customary for short-term and long-term storage of viable bacterial cultures.

Survival during passage through rats. During construction of x1776, the ability of various strains to survive and/or multiply during passage through the intestinal tract of rats has been tested repeatedly to determine which mutations were or were not important in precluding such survival. High concentrations of cells have been fed by using a stomach tube so that measured quantities of cells could be delivered down the esophagus. Cells were always suspended in milk so as to circumvent, as much as possible, problems associated with the acidity of the stomach. In general, weanling rats have been used although older rats have also been tested. The results of some of these tests are summarized in Table 13.

The prototroph x1833 (x289 Nal^r) survives this passage rather well and indeed must multiply to some extent to explain the excretion of between 10⁶ and 10⁸ cells per 0.1 g feces during the first day or two after feeding and the continued excretion for several days. x1922 which is a *thyA* derivative of x1833 survives slightly less well than x1833 which indicates that the *thyA* mutation must provide some selective disadvantage during passage through the intestinal tract. This point has been verified in tests with other *thyA* strains. x1841, which is the Nal^r derivative of x1488 [the first strain derived from x1276 during the construction of x1776 (see Chart C)], has above the same survival characteristics as x1922. The double Dap^r strain x1846, which can still synthesize colanic acid, survives a little less well and x1849, which was isolated from x1846 and cannot produce colanic acid, is killed off even more rapidly. All these strains, however, do survive passage through the intestinal tract. It is therefore evident that the six hours that it takes a fed strain to appear in feces is an insufficient length of time to permit enough metabolism for 100% DAP-less death to occur.

The various bile salts sensitive derivatives of x1849, however, have never been observed to survive passage through the intestinal tract under normal conditions (Table 13). A further indication of the importance of the bile salts sensitivity trait is the ability of x1925 and x1928 (two bile salts resistant revertants of x1776 and x1876, respectively) to survive passage through the intestinal tract. Neither of these strains survives as well as x1849, however, but this may be explainable if x1925 and x1928 do not represent true revertants for the bile salts sensitivity trait. Indeed, the bile salts resistant derivative x1926, which is still partially bile salts sensitive (Table 6) and is therefore probably not a true revertant, does not survive passage through the rat's intestinal tract. Five different x1776 derivatives that were selected for their ability to grow or form larger colonies on various media were also unable to survive passage through the rat's intestine. A TS^r revertant of x1776 (x1929) fared no better. A *deoC* derivative of x1776 (x1930) that can grow with low levels of thymine also cannot survive passage through the rat's intestine. In this regard, it is known from studies with other strains that the *deoC* mutation decreases intestinal survival of *thyA* strains although the *deoB* mutation has no effect.

Of some interest is the observation that the feeding of tetracycline to the rats for one day prior to and during feeding of x1876 results in survival of some x1876 cells. The dose of tetracycline given was rather high so it might be that DAP-less and/or thymineless death was inhibited due to tetracycline-induced growth inhibition, in which case the lower survival of x1876 was probably due to bile salts sensitivity. This explanation is partially validated by the observation that the x1876 bile salts resistant derivative, x1928, gave higher surviving titers in feces following tetracycline feeding than did x1876. These results, however, emphasize the need to

follow the dictum that individuals working with recombinant DNA molecules should not engage in such work during and for seven days after cessation of antibiotic therapy.

POTENTIAL FOR TRANSMISSIBILITY OF GENETIC INFORMATION BY STRAINS.

Conjugational recipient ability under permissive conditions. Since conjugational transmission of chimeric plasmids may well be the most likely means for successful escape and perpetuation of cloned DNA, over five hundred matings were performed with χ_{1776} , its derivatives and its ancestors to assess recipient and donor ability under a diversity of conditions; 22 different conjugative plasmids that represent 15 different incompatibility groups were employed for these studies.

In terms of recipient ability χ_{1841} , χ_{1849} and χ_{1776} were mated with 22 donors, each with a different conjugative plasmid and which collectively represent 15 incompatibility groups. These matings have been performed under optimal permissive conditions to assess the contributions of different mutations in χ_{1776} to diminish its recipient ability. Since plasmids in certain incompatibility groups are prevalent in microorganisms that inhabit soil, water, the intestinal tracts of fish, etc., these matings were carried out at 27, 32 and 37°C. to assess the contribution of temperature to the efficiency of plasmid transfer. Most of these matings were conducted for 24 hours with transconjugant yields and parental titers being determined after 30 and 90 minutes and 24 hours of mating. It became readily apparent, however, that the viable χ_{1776} titer dropped 10 to 10,000 fold after 24 hours of mating at 37°C. and since this would also account for the observed decrease in transconjugant titers, 24 hour matings were discontinued to evaluate χ_{1776} 's recipient ability. This behaviour was noted in matings with 11 different donors (the other 11 were not examined for this property). Of interest is the fact that χ_{1776} remains viable and indeed grows at 32°C. in the presence of other bacteria provided that DAP is present.

Recipient ability of χ_{1776} has been tested with donors harboring conjugative plasmids in the C, FI, FII, H, I α , J, L, M, N, O, P, T, W, X, 9, and 10 incompatibility groups. For matings under optimal permissive conditions at 37°C., the frequency of transfer was 10^{-1} for one I-type plasmid (R64-11), 10^{-2} for various FII plasmids, 10^{-3} to 10^{-4} for the N and other I α plasmids, 10^{-5} for P plasmids, 10^{-6} for Inc 9 plasmids, 10^{-7} for L, M, and Inc 10 plasmids, 10^{-8} for T plasmids, and less than 10^{-9} for C, H, and X plasmids.

Generally, matings conducted at the lower temperature of 32°C. resulted in a decreased transconjugant frequency. There were, however, three exceptions to this behaviour: R27 (H), R831 (L), and R394 (T) were able to transfer 1000-fold, 10-fold, and 100,000-fold better, respectively, at 32°C. The recipient ability of χ_{1776} for R831 and R394 decreased about 10-fold when the mating temperature was further reduced to 27°C., but for R27 there was another 10-fold increase in transconjugant frequency at the lower temperature. When the mating temperature was 22°C., the transconjugant frequency was about the same as when matings with the donor possessing R27 had been conducted at 32°.

The lower temperature of 27°C. also appears to increase the transconjugant frequency in matings between χ_{1776} and donors possessing C or M type plasmids, although the frequencies are quite low: 10^{-7} and 10^{-6} , respectively. With all other plasmids, except the ones mentioned above, transconjugant frequencies from matings conducted at 27°C. were decreased in comparison to those obtained in matings at 37°C. or 32°C. and were, in fact, quite low: 10^{-6} to less than 10^{-9} .

The ability of χ_{1776} to receive plasmids from the various donors under optimal permissive mating conditions, when compared to the recipient ability of χ_{1841} , shows the following pattern:

1. the transconjugant frequency for χ_{1776} is less than 10-fold lower than that for χ_{1841} . This behavior was demonstrated by one FII and three I-type plasmids and plasmids of the H, N, P, W, and 9 incompatibility groups. For most of these plasmids, the recipient ability of χ_{1776} was 2- to 6-fold lower than that of χ_{1841} , but χ_{1776} was actually able to receive RP4, a P-type plasmid, at about twice the frequency at which χ_{1841} received the same plasmid.

2. the transconjugant frequency for χ_{1776} was 10- to 100-fold lower than that for χ_{1841} . Included in this group were the other FII and one I-type plasmid, C, and M-type plasmids.

3. the transconjugant frequency for χ_{1776} was 1000-to 100,000-fold lower than

that for χ_{1841} . Plasmids of the J, L, O, T, X, and 10 incompatibility groups exhibited this type of behaviour.

In other matings with χ_{1849} , which possesses the $\Delta 40[gal-uvrB]$ mutation, it has been possible to show a significant reduction in transconjugant frequency compared to the recipient ability of χ_{1841} for conjugative plasmids in the C, J, L, M, O, T, X, and 10 incompatibility groups. Thus the $\Delta 40[gal-uvrB]$ mutation contributes to the Con^{-} phenotype of χ_{1776} . By using χ_{1925} , a bile salts resistant revertant of χ_{1776} , it has also been possible to show that the decreased recipient ability of χ_{1776} for certain conjugative plasmids is due to the combined effects of the *rjb-2*, *oms-1* and *oms-2* mutations.

In terms of evaluating the ability of χ_{1776} to acquire a conjugative plasmid which would be necessary for the mobilization and transmission of a non-conjugative plasmid vector, several factors should be considered. First, it should be mentioned that *R1drd19*, *R100drd1*, *R64drd11* and *R549drd1* are derepressed for expression of the donor phenotype such that donors that possess them are (or should be) 100- to 10,000 times for fertile than donors possessing wild-type repressed conjugative plasmids. Indeed, only three derepressed conjugative plasmids have ever been isolated in nature; namely, F (which might have actually mutated during its 40 years sojourn in *E. coli* K-12), ColV and one R plasmid. These derepressed plasmids were therefore used only to maximize the ability to detect rare events. However, it should be noted that donors harboring R648 (*IncI α*) and R66a-1 (*IncI α*) give transconjugant yields in matings with χ_{1841} that are approaching those expected for transfer of derepressed plasmids. Second, the yield of transconjugants inheriting *IncI α* and *IncFII* plasmids decreases as the square of the dilution in the bacterial mating density below 10^8 cells/ml. Thus, transconjugant yields are decreased about 10,000-fold for matings of one hour duration conducted at cell densities of 10^5 /ml which is the approximate density of *E. coli* found in the mammalian intestinal tract. Third, there exist other barriers to acquisition of conjugative plasmids in nature which include the frequency of potential donors possessing conjugative plasmids (about 10 percent), the presence of restriction-modification systems in most microorganisms and the existence of entry exclusion, incompatibility and donor cell surface properties. All of these factors greatly diminish the likelihood that χ_{1776} containing a non-conjugative plasmid could acquire such a conjugative plasmid in nature. The low survival potential of χ_{1776} in natural environments would also make it highly unlikely that χ_{1776} could ever survive long enough to transmit recombinant DNA to other organisms even if it did acquire such a conjugative plasmid.

Mobilization of pSC101 by conjugative plasmids under permissive conditions. In order to evaluate the consequences of the acquisition of a conjugative plasmid by χ_{1776} on the subsequent potential to transmit DNA cloned on the pSC101 non-conjugative plasmid vector, derivatives of χ_{1876} were constructed that possessed various conjugative R plasmids that did not express tetracycline resistance. All these R plasmids were stable in χ_{1876} and did not cause χ_{1876} to lose pSC101 during cultivation at 37°C. These donors were then mated with χ_{1763} and the titers of both parents and all transconjugant classes measured after 1, 6 and 24 hours at 37°C. In addition to providing data on the mobilization of pSC101, these matings also evaluated the potential of χ_{1876} (and thus χ_{1776}) to act as donors of the various conjugative plasmids. It was found that χ_{1876} exhibits normal donor ability during 60 minutes of mating for the transfer of *R1drd19*, *R549drd1*, *R69/2*, *R66a-1* and *R648* and is defective in the transfer of *R394* and *R40a* when compared to the donor ability of χ_{1753} derivatives harboring these plasmids. It should be noted, however, that the recipient ability of χ_{1776} for the *IncT* plasmid *R394* is almost 5,000 times higher in matings at 27°C. than in matings at 37°C. and it is thus conceivable that the donor ability of a χ_{1876} derivative harboring *R394* might also increase with a decrease in mating temperature. In any event, it is evident that the *IncM* plasmid *R69/2* mobilizes pSC101 as efficiently as itself and compared to their own transfer frequencies that the *IncI α* plasmids *R549drd1* and *R648* mobilizes pSC101 at a 10^{-1} to 10^{-2} frequency, that the *IncI α* plasmid *R66a-1* mobilize pSC101 at a 10^{-2} to 10^{-3} frequency and that the *IncFII* plasmid *R1drd19* mobilizes pSC101 at a 10^{-3} to 10^{-4} frequency. The *R40a* (*IncC*) and *R394* (*IncT*) plasmids did not give detectable frequencies of pSC101 mobilization. χ_{1876} donors generally decreased in titer during the 24 hours of mating. It should be noted, however, that although the total χ_{1763} titer increased about 10-fold between 6 and 24 hours of mating, the χ_{1763} derivatives inheriting pSC101 (with or without the conjugative R plasmid) did not increase at all and even decreased during this same interval. Since the

transconjugants selected for inheriting the conjugative plasmid alone did increase in titer during this interval, it is inferred that many of the stationary phase \times 1763 cells that possessed pSC101 could not plate on medium with 12.5 μ g tetracycline/ml. This inference is based on the fact that expression of the tetracycline resistance specified by pSC101 is inducible and not constitutive and the fact that stationary phase cells, when placed in conditions for growth, are poorly equipped to immediately begin synthesis of a protein needed for their survival.

Triparental matings under permissive conditions. As another means to assess the likelihood that \times 1776 possessing a chimeric plasmid could transmit the cloned DNA to some other microorganism, triparental matings were performed using a series of \times 1753 derived primary donors in matings with \times 1876 and the secondary recipient \times 1763. In these matings, conducted under optimal permissive conditions at 37°C., pSC101 was transferred to \times 1763 in the presence of primary donors possessing the derepressed I α plasmid R549*drd1* (10⁹/ml), the I α plasmids R648 and R66a-1 and the L plasmid R471a (10⁹/ml), the derepressed FI plasmid F'*his*⁺ and the M plasmid R69/2 (10⁹/ml), the derepressed FII plasmid R1*drd19* and the T plasmid R394 (10⁹/ml). No pSC101 transmission was detected in matings with primary donors possessing one C and one Inc10 group plasmid. Of interest is the observation that triparental matings with the donors possessing the R394 plasmid yielded very low frequencies of pSC101 transconjugants in \times 1763, whereas \times 1876 derivatives harboring R394 did not yield pSC101 transconjugants in matings with \times 1763 (except for a few colonies after 24 hours of mating with the R40a⁺ donor). The decline in \times 1876 titer during the course of mating in some but not all matings was also apparent from the data obtained.

Conjugational ability during DAP-less and/or thymineless death. Studies on the recipient and donor ability of \times 1776 and \times 1876 under non-permissive conditions were restricted to studies using the derepressed IncFII plasmid R1*drd19*. A \times 1776 derivative possessing R1*drd19* loses the ability to transfer R1*drd19* to \times 1763 at a rate that is proportional to the rate of donor cell death. Indeed, surviving R1*drd19* \times 1776 cells are almost as efficient on a per cell basis as non-starving R1*drd19* \times 1776 cells in conjugational plasmid transfer. This is also true for starvation in ML medium with or without Casamino acids where starvation for thymine might be expected to block conjugational plasmid transfer even by surviving cells. Obviously, either these surviving cells have a sufficient pool of thymine-containing nucleotides to support conjugational plasmid replication or conjugational plasmid transfer does not depend on concomitant conjugational DNA replication.

Conjugational ability as a function of starvation time in non-growth liquid media. The ability of \times 1776 to receive R1*drd19* from \times 1792 was measured as a function of starvation and mating time in water, BSG and ML + glucose at 24°C. and 37°C. Transconjugants were essentially undetectable for matings in water and BSG at both temperatures and were diminished 10,000 to 100 fold for matings in ML + glucose at 24°C. and 37°C., respectively, compared to yields observed in L broth matings under permissive conditions. When \times 1792 and \times 1776 were starved for 4 hours in these non-growth media, transconjugants were either absent or decreased another 10 to 100 fold over what was observed without starvation. In general, recipient ability is retained better during starvation in ML + glucose than in BSG and at 37°C. than at 24°C. It should be noted that these measures of \times 1776's recipient ability cannot be due to plate matings, since nalidixic acid was included in the selective medium and immediately causes plasmid transfer to cease. It is interesting to note that although growth of cells possessing IncF group plasmids at 28°C. or less yields phenocopies; unable to mate, starvation at 24°C. of donor cells that were originally grown at 37°C. does not abolish \times 1792's donor fertility. It is known that starvation of donor cultures at 37°C. also leads to loss of donor fertility although starvation as a standing culture without vigorous aeration causes the lowest rate of loss in donor ability and this may account for the low yield of transconjugants formed at 37°C.

The donor ability of \times 1776 containing the R1*drd19* plasmid was also measured with and without starvation in water, BSG and ML + glucose at 23, 37 and 43°C. No plasmid transfer to \times 1763 was observed for any matings at 43°C. nor for matings in water or BSG at 23°C. Donor ability was decreased 100 to 10⁷ fold for all other conditions with water being the poorest mating condition.

These studies indicate that most of the non-permissive conditions likely to be encountered in nature will not be conducive to conjugational transmission of plasmid chimeras.

Potential for transductional transmission under non-permissive conditions. In view

of the increased resistance of λ 1776 and λ 1876 to infection by P1L4, it was decided to study the production of other phages in λ 1776 under non-permissive conditions. One reason for doing this is that the changes in λ 1776's cell surface that result in resistance to well-studied *E. coli* phages can also result in sensitivity to other phages which have not been well studied and which therefore might be capable of transduction. Evidence for the reversal of phage sensitivity patterns during the derivation of λ 1776 was found. In one experiment, the ability of λ 1776 after 0 and 4 hours starvation in BSG and ML + glucose to be productively infected with T6 phage was measured. T6 can be produced inefficiently by λ 1776 under starvation conditions even in the absence of a carbon source. Starvation for 4 hours prior to infection gave better yields than did starvation for 0 hours and this is most likely due to the starvation-induced turnover of proteins and other cellular constituents to provide raw materials for phage development. Latent periods under these conditions were long (2 to 3 hours) and burst sizes small (about 50), however.

Potential for transformation under non-permissive conditions. The fact that λ 1776 and λ 1876 lyse under growth conditions in the absence of DAP leads to the question as to whether the DNA released by such lysing cells might not be taken up and transform other bacterial cells in the same environment. DNA released by λ 1776 and λ 1876 during DAP-less death is rapidly degraded when the lysis occurs in cultures of reasonably high density (10^7 to 10^9 cells/ml) in which case the released nucleases are probably present in high enough concentrations to degrade the released DNA. However, such cell densities are not likely during lysis of escaped bacteria in nature and one must therefore determine whether nucleases are present in these natural environments. It was found that DNA is very rapidly degraded when added to the intestinal contents of both conventional and germ-free sacrificed rats and is therefore unlikely to survive long enough to transform other bacteria.

Most microbial geneticists think of the need for incubating gram-negative bacteria at 0°C. in the presence of CaCl_2 followed by a rapid temperature shift to 30 to 42°C. to obtain transformation, and although these conditions are not likely to be encountered in nature, such conditions might not be necessary. For example, it might be possible to obtain transformation of *E. coli* with plasmid DNA at 37°C. by simultaneous infection with a helper virus, although such a possibility has never been examined.

FEATURES AFFECTING UTILITY OF STRAINS.

Transformability. λ 1776 is more transformable with pSC101 plasmid DNA than its ancestor λ 1841 (λ 1488 Nal^r) but less transformable than its ancestor λ 1849. These results indicate that the $\Delta[\text{gal-uvrB}]$ mutation improves transformability and that the mutations conferring bile salts sensitivity decrease it. Several different transformation procedures were tried and since none of the previously described methods were satisfactory for λ 1776 a new procedure was developed as described hereinafter.

Plasmid curing. The growth of λ 1876 at 41°C. but not at 37°C. results in loss of the pSC101 plasmid. This feature might be of some use. Derivatives of λ 1876 cured of pSC101 were also examined to see if they gave higher yields of pSC101 transformants than λ 1776 and no difference was measurable.

Minicell production. During the construction of λ 1776, an effort was made to always select good minicell producers. λ 1776 and λ 1876 cultures possess 1 to 2 minicells per cell. These have been easily purified from the parental cells that produce them by two successive bandings on linear 5 to 20% sucrose in BSG gradients using the SW 27 rotor in a Beckman (Trademark) preparative ultracentrifuge to yield minicell preparations that contain only 1 contaminating bacterial cell in 10^6 to 10^7 minicells. It should be mentioned that these surviving contaminating cells can be completely eliminated by incubating the minicells in a growth medium lacking DAP. Since minicells can neither grow nor divide, they are completely resistant to DAP starvation and minicells from λ 1876 retain the pSC101 plasmid in an undegraded state during 24 hours of starvation for DAP and thymine.

Since the minicells produced by λ 1776 and λ 1876 can survive for long periods of time, some comments are in order about their potential for transmission of genetic information. About 1 out of 10,000 plasmid-containing minicells can be productively infected with T4 bacteriophage and yield a small burst after a prolonged latent period. P1kc can also infect minicells harboring the ColVB-trp plasmid (110×10^6 daltons) and can yield transducing phages capable of giving

Trp⁺ transductants. In these experiments, 1 out of 10,000 minicells was productively infected, the burst size was 10 and about 1 out of 500 P1_{kc} particles was capable of transduction of a *trp*⁻ strain. Thus, the overall yield of transducing phages was extremely low.

In terms of conjugational transmission of plasmid DNA from minicells, it is known that minicells can act as recipients for plasmid DNA. When these minicell recipients come from an F⁻ strain and are therefore DNA deficient, they cannot convert conjugationally transferred single-stranded plasmid DNA to a double-stranded circular form and cannot carry out transcription and translation that would be necessary to express the donor phenotype. Minicells produced by a strain harboring a conjugative plasmid can, however, transfer that plasmid at low frequency to F⁻ cells. Since plasmid-containing minicells can carry out transcription and translation, it is remotely possible that minicells harboring a non-conjugative plasmid might be able to receive conjugative plasmid single-stranded DNA and then convert this to a double-stranded circular form and carry out the synthetic activities to permit the minicell to become a conjugationally proficient donor.

Monitoring and precluding contamination during recombinant DNA molecule experiments. *x*1776 and *x*1876 are resistant to nalidixic acid, cycloserine and trimethoprim and since resistance to nalidixic acid and cycloserine among bacteria in nature is rare and is not known to be plasmid mediated, these antibiotics are useful additives to cultures of *x*1776 and derivatives as a means to preclude contamination of cultures with robust microorganisms from the laboratory environment. This may be particularly important as a means to preclude transformation of a robust contaminant during DNA cloning experiments. In this regard, it should be mentioned that nalidixic acid is stable to autoclaving at normal pH's and thus is difficult to destroy before disposal into the environment. Cycloserine may be preferable since it is less expensive and has a normal half life of about one day at 37°C. at neutral pH. It must therefore be prepared freshly each day and suspended in a pH 8 phosphate buffer until use.

In terms of monitoring *x*1776 and *x*1876 in the presence of high concentrations of other microorganisms, the use of nalidixic acid is far superior to use of cycloserine. Nalidixic acid resistance is an infrequent mutational event and nalidixic acid completely obliterates background growth of sensitive cells even when plating 10⁹ cells per plate. Cycloserine, on the other hand, permits background growth of sensitive cells when plating densities exceed 10⁷ cells per plate.

The testing data obtained indicate that *x*1776 possesses properties in conformance with the stated goals for genetically constructing a safer, more useful host microorganism for recombinant DNA molecule research. Improvements can be made, however; these improvements are as follows:

i. *thyA* mutation reverts at low frequency — replace with non-reverting *ΔthyA57* mutation.

ii. thymineless death leads to accumulation of *deoB* and *deoC* mutants that are efficient scavengers of thymine — introduce *deoA* and *upp* mutations to abolish ability to use thymine.

iii. DNA degradation during thymineless death is not as rapid or complete as would be desirable — introduce *deoA* and *upp* mutations and *polA*(CS) and *recA* mutations.

iv. mutations conferring sensitivity to bile, ionic detergents, drugs, antibiotics, etc. and Con⁻ phenotype revert at low frequency — add additional mutations in *con*, *rfa*, *lpcA* and/or *lpcB* genes.

v. *Δ29[bioH-*asd*]* mutation confers resistance to λ thus precluding use of λ cloning vectors — replace with *dapA* or *dapE* mutation.

vi. transformability can be improved — introduce *endA* mutation.

All of the above-mentioned improvements have been shown to work and methods have been developed and implemented in the genetic construction of other safer, more useful hosts for recombinant DNA molecule research (see Charts D and E).

TABLE 3.
Plasmids.

Strain Number	Plasmid	Incompatibility Group	Plasmid Genotype and Phenotype
<i>x</i> 1632 ^a	pSC101	—	Tc ^r
<i>x</i> 1779	F'	IncFI	<i>his</i> ⁺
<i>x</i> 1780	R64 <i>drd11</i>	IncI α	<i>drd11</i> Sm ^r Tc ^r
<i>x</i> 1782	R6K	IncX	Sm ^r Ap ^r
<i>x</i> 1783	R549 <i>drd1</i>	IncI α	<i>drd1</i> Sm ^r Km ^r
<i>x</i> 1784	R100 <i>drd1</i>	IncFII	<i>drd1</i> Tc ^r Cm ^r Su ^r Sm ^r Sp ^r
<i>x</i> 1785	R16	IncO	Sm ^r Su ^r Tc ^r
<i>x</i> 1786	RP4	IncPI	Ap ^r Tc ^r Km ^r
<i>x</i> 1787	N—3	IncN	Tc ^r Sm ^r Su ^r
<i>x</i> 1788	R40a	IncC	Ap ^r Km ^r Su ^r
<i>x</i> 1789	R27	IncH	Tc ^r
<i>x</i> 1791	R394	IncT	Ap ^r Km ^r
<i>x</i> 1792	R1 <i>drd19</i>	IncFII	<i>drd19</i> Cm ^r Km ^r Ap ^r Sm ^r Sp ^r Su ^r
<i>x</i> 1793	S-a	IncW	Sm ^r Cm ^r Su ^r Km ^r
<i>x</i> 1895	R391	IncJ	Km ^r
<i>x</i> 1896	R471a	IncL	Am ^r
<i>x</i> 1898	R69/2	IncM	Ap ^r Km ^r
<i>x</i> 1900	R72	Inc10	Km ^r
<i>x</i> 1901	R71a	Inc9	Ap ^r Sm ^r Cm ^r Tc ^r Su ^r
<i>x</i> 1906	R648	IncI α	Ap ^r Sm ^r Km ^r
<i>x</i> 1907	R66a-1	IncI α	Ap ^r Sm ^r Km ^r
<i>x</i> 1924	pR0164	IncPI	Tp ^r Cb ^r
<i>x</i> 2026	R15	IncN	Sm ^r Su ^r
<i>x</i> 2027	R831	IncL	Sm ^r Km ^r

^a All plasmids in *x*1753 background except *x*1632 which has the chromosomal genotype: *thr-1 leu-6 tonA21 lacY1 supE44 λ^- thi-1*.

TABLE 4.
Phenotypic Properties of $\times 1776$.

Phenotype	Responsible Mutation(s)
Requires DAP	<i>dapD8</i> $\Delta 29[bioH-asd]$
Requires threonine	$\Delta 29[bioH-asd]$
Requires methionine	<i>metC65</i> $\Delta 29[bioH-asd]$
Requires biotin	$\Delta 40[gal-uvrB] \Delta 29[bioH-asd]$
Requires thymidine	<i>thyA57</i> *
Cannot use galactose for growth	$\Delta 40[gal-uvrB]$
Cannot use maltose for growth	$\Delta 29[bioH-asd]$
Cannot use glycerol for growth	$\Delta 29[bioH-asd]$
Cannot synthesize colanic acid	$\Delta 40[gal-uvrB]$
Sensitive to UV (defective in dark and photo repair)	$\Delta 40[gal-uvrB]$
Sensitive to glycerol (aerobic)	$\Delta 29[bioH-asd]$
Sensitive to bile salts, ionic detergents, antibiotics and drugs	<i>rfb-2</i> plus additional mutations <i>oms-1</i> and probably <i>oms-2</i>
Resistant to nalidixic acid	<i>nalA25</i>
Resistant to cycloserine	<i>cycA1 cycB2</i>
Resistant to chlorate (anaerobic)	$\Delta 40[gal-uvrB]$
Resistant to trimethoprim	<i>thyA57</i> *
Resistant to T1, T5, $\phi 80$	<i>tonA53</i>
Resistant to λ and 21	$\Delta 29[bioH-asd]$
Partially resistant to P1	<i>rfb-2</i> plus additional mutations <i>oms-1</i> and probably <i>oms-2</i>
Conjugation defective	$\Delta 40[gal-uvrB] rfb-2 plus additional mutations oms-1 and probably oms-1$
Produces minicells	<i>minA1 minB2</i>
Temperature sensitive at 42°C.	<i>oms-2</i> mutation linked to <i>thyA57</i> * plus <i>oms-1</i> in conjunction with <i>rfb-2</i>

The *thyA57** mutation may be derived from the Δ *thyA57* allele but since it reverts it has been designated with an asterisk.

TABLE 5.
Stability of Genetic Markers in x_{1776} and x_{1876}^a .

Reversion to	Revertant Frequency in x_{1776}	Revertant Frequency in x_{1876}
Dap ⁺	$<2.6 \times 10^{-10}$	$<1.7 \times 10^{-9}$
Bio ⁺	$<2.6 \times 10^{-10}$	$<1.7 \times 10^{-9}$
Mal ⁺	$<2.6 \times 10^{-10}$	$<1.7 \times 10^{-9}$
Gal ⁺	$<2.6 \times 10^{-10}$	$<1.7 \times 10^{-9}$
Met ⁺	$<2.6 \times 10^{-10}$	$<1.7 \times 10^{-9}$
Thr ⁺	$<2.6 \times 10^{-10}$	$<1.7 \times 10^{-9}$
Thy ⁺ (CAA) ^b	1.8×10^{-9d}	1.5×10^{-9d}
Thy ⁺ (SMA) ^c	9.8×10^{-9d}	6.7×10^{-9d}

^aCultures of x_{1776} and x_{1876} were grown with shaking for 12 hr at 37°C. The cultures were sedimented, washed once with BSG + DAP, and the pellet was suspended at one-fortieth of the original volume in BSG + DAP + nalidixic acid (25 μ g/ml). A minimum of 0.8 ml of the undiluted x_{1776} and 0.2 ml of the undiluted x_{1876} cultures were spread on each type of medium selecting for revertants; 0.4 ml, 0.1 ml and 0.1 ml of the 10^{-1} , 10^{-2} , and 10^{-3} dilutions, respectively, were also plated.

^bThese Thy⁺ revertants were isolated on MA + 1% Casamino acids, 0.5% Glc, DAP, Bio.

^cThese Thy⁺ revertants were isolated on MA + 0.5% Glc, Thr, Met, DAP, Bio (Supplemented Minimal Agar).

^dThe apparent frequencies of Thy⁺ revertants were slightly higher than indicated since some Thy⁻ *deoB* or *deoC* mutants were able to form colonies on these plates (presumably due to release of thymine as a consequence of thymineless death of the majority of cells). The mean frequency of such *deoB* or *deoC* mutants was 1.3×10^{-9} .

TABLE 6.
Stability of Phenotypic Traits in \times 1776 and \times 1876^a.

Strain	Medium for selection	Phenotypic traits	Frequency	Derived Strains
\times 1776	MA + CAA, DAP, Bio, Glc + 2 μ g thymine/ml	Require low levels of thymine	1.1×10^{-6}	—
		Resistant to Thd and dAdo (<i>deoB</i>) ^b	1.0×10^{-6}	\times 1931
		Sensitive to Thd and dAdo (<i>deoC</i>) ^b	1.3×10^{-7}	\times 1930
\times 1776	L agar + DAP, Thd at 42°C.	See text	1.7×10^{-5c}	\times 1929
\times 1876	MacConkey agar + DAP, Thd, Bio	Large colony types that plate at high efficiency on MacConkey Agar and L agar + 0.15% bile salts	2.5×10^{-9}	—
		Small colony types that plate at high plating efficiency on MacConkey agar but do not plate on L agar + 0.15% bile salts	6.3×10^{-9}	—
\times 1776	MacConkey agar + DAP, Thd, Bio	Large colony types that plate at high plating efficiency on MacConkey agar and L agar + 0.15% bile salts	1.3×10^{-9}	\times 1925
		Small colony types that plate at high plating efficiency on MacConkey agar but do not plate on L agar + 0.15% bile salts	6.0×10^{-9}	\times 1926

TABLE 6 (continued).

Strain	Medium for selection	Phenotypic traits	Frequency	Derived Strains
x1776	L agar + DAP, Thd + 0.15% bile salts	Small colony types that plate on L agar x 0.15% bile salts but not on MacConkey agar	7.8×10^{-6}	x1927
x1776	Penassay agar + DAP, Thd + 0.75% bile salts	Large colonies that plate on MacConkey agar	5.0×10^{-10}	—
x1776	Penassay agar + DAP, Thd + 0.37% bile salts	Large colonies that plate on MacConkey agar	1.0×10^{-9}	—
x1776	Penassay agar + DAP, Thd + 0.1% sodium dodecyl sulfate	—	1.0×10^{-10}	—
x1776	Penassay agar + DAP, Thd + 0.1% sarkosyl	Large colony type Small colony type	5.0×10^{-9} 1.5×10^{-9}	— —

^aCultures were grown to exponential phase in L broth + DAP, Thd, sedimented by centrifugation, concentrated by suspension in L broth + DAP, Thd and plated on media indicated.

^bResistant or sensitive to 1 mM thymidine and 1 mM deoxyadenosine in MA. ^cFrequency based on titer of regular-sized colonies that would grow at 42°C. after restreaking reasonably dense suspensions on L agar + DAP, Thd. These same suspensions grew better at 37°C. than at 42°C., however. There were about twice the frequency of small colonies that did not grow at 42°C. when restreaked.

TABLE 7.
Selection of Various Transductant Types from λ 1776^a.

Marker Selected	Plating Medium	No. Revertants per ml	No. Transductants per ml	Transductant Frequency
Thr ⁺	MA + Met, Bio, DAP, Thd, Glu	0	65	2.3×10^{-7}
Mal ⁺	MA + Thr, Met, Bio, DAP, Thd, Mal	0	32	1.1×10^{-7}
Thr ⁺ Mal ⁺	MA + Met, Bio, DAP, Thd, Mal	0	42	1.5×10^{-7}
Glyc ⁺	MA + Thr, Met, Bio, DAP, Thd, Glyc	0	28	9.9×10^{-8}
Bio ⁺	MA + Thr, Met, DAP, Thd, Glu	500 ^b	243 ^b	8.6×10^{-7}
Bio ⁺	MA + CAA, DAP, Thd, Glu	0	0	$<1.7 \times 10^{-8}$
Met ⁺	MA + Thr, Bio, DAP, Thd, Glu	0	0	$<1.7 \times 10^{-8}$
Thy ⁺	MA + Thr, Met, Bio, DAP, Glu	0	180	6.3×10^{-7}
Dap ⁺	Penassay agar + Thd	0	13	4.6×10^{-8}
Gal ⁺	MA + Thr, Met, Bio, DAP, Thd, Gal	0	5	1.8×10^{-8}

^a λ 1776 was grown in LB containing DAP, Bio, Thd and 2.5×10^{-3} M CaCl₂ to log phase and PIL4 (289) was added at a multiplicity of 0.76. After 30 min at 37°C., Na citrate was added to 0.14 M and after 10 min samples were plated on the indicated media.

^b When these colonies were picked into drops of BSG + DAP and restreaked on selective media, they failed to give rise to any Bio⁺ colonies even after one week of incubation.

TABLE 8.
Efficiencies of Plating of $\times 1776$ on Various Antibiotic-containing Media^a.

	MA + 0.5% Glc, 1% CAA, DAP, Bio,					L agar DAP, Thy					EMB + 1% Mtl, Ade, DAP, Bio,				
	Thy										Thy, Pdx				
μg NaI/ml	0	25	50	75	100	0	25	50	75	100	0	25	50	75	100
	1.25	1.20	1.10	0.99	1.10	1.00	1.01	0.84	0.77	0.50	0.90	0.79	0.68	0.71	0.64
	MA + 0.5% Glc, Thr, Met, DAP					L agar + DAP, Thy, Cyc ^{6b}					EMB + 1% Mtl, Ade, DAP, Bio,				
μg NaI/ml	Bio, Thy										Thy, Pdx Cyc ^{6b}				
	0	25	50	75	100	0	25	50	75	100	0	25	50	75	100
	1.33	1.30	1.30	1.30	1.00	1.00	0.98	0.79			1.02	0.90	0.99	0.88	0.90
μg Cyc/ml	MA + 0.5% Glc, Thr, Met, DAP														
	Bio, Thy														
	1.5	5	10	15	20	25									
	0.70	1.10	0.95	1.30	0.91	1.10									

^aStrains were grown exponentially in L broth + Thy + DAP at 37°C. to a density of approximately 1×10^8 cells/ml. Each culture was diluted in BSG + DAP + Thy and plated on the media listed in the table. The cell titer determined on L agar + DAP + Thy was arbitrarily designated as a plating efficiency of 1.00 and was used as the standard for determining all other efficiencies of plating.

^bCyc: cycloserine; the superscript indicates the final concentration ($\mu\text{g}/\text{ml}$) in the medium.

TABLE 10.
Cross-streak tests for phage sensitivity^a.

Phage	Bacterial strain ^b					Phage	Bacterial strain ^b				
	x1833	x1841	x1849	x1776	x1925		x1833	x1841	x1849	x1776	x1925
T1	S	S	R	R	R	φII	R	S	S	S	S
T2	S	S	S	S	S	φW	R	R	S	R	S
T3	R	R	S	S	S	φH	S	S	S	S	S
T4	S	S	S	S	S	PV	S	S	S	R	S
T5	S	S	R	R	R	Qβ	R	R	R	R	R
T6	S	S	S	S	S	MS-2	R	R	R	R	R
T7	S	S	S	S	S	R ₁₇	R	R	R	R	R
<i>λvir</i>	S	S	R	R	R	fcan1	R	R	R	R	R
434	S	S	S	S	S	f1	R	R	R	R	R
φ80	S	R	R	R	R	If2	R	R	R	R	R
P1L4	S	S	S	R	S	6SR	S	S	S	S	S
D108	S	S	S	R	S	Ffm	R	R	R	R	R
Mu-1	S	S	R	R	R	Br60	S	S	S	R	S
φ12	ND	S	R	S	R	FP1	S	R	S	R	R
φ14	S	R	S	S	S	FP3	S	S	S	S	S
φ15	ND	R	S	S	S	BR10	S	S	S	S	S
21	ND	S	ND	R	ND	BF23	S	S	S	S	S
S13	R	R	S	S	S	C21	R	R	S	R	S

^aPhage sensitivity was determined by cross-streaking full loopfuls of log-phase bacterial cultures against phage on EMB + 0.1% glucose, DAP, Thy (Curtiss, 1965). x1776 and x1876 form light red streaks on EMB + 0.1% glucose due to what appears to be periplasmic leaking; it was therefore necessary to score these streaks on the basis of detectable lysis or no lysis after 12 and/or 24 hr incubation at 37°C.

^bIdentical results were obtained for both x1776 and x1876 and likewise for x1925 and x1928. Two other bile salts resistant revertants of x1776, x1926 and x1927 (see Table 6), retained the phage sensitivity pattern of x1776 for response to D108 and φ12 but became sensitive to P1L4. They were not tested for response to φW, PV, Br60 and C21 which also distinguish x1776 from x1925. ND = not done.

TABLE 11.
Ability of P1L4 to Form Plaques and Transduce $\times 1776$ and its Ancestors.

Host Strain	Efficiency of plating ^a	Transduction ^b	
		Marker Selected	Frequency
$\times 1488$	0.65	—	—
$\times 1678$	0.80	—	—
$\times 1697$	0.87	—	—
$\times 1702$	1.64	Ilv ⁺	3.9×10^{-5}
$\times 1777$	1.47	—	—
$\times 1820$	0.96	Ilv ⁺	5.2×10^{-5}
$\times 1845$	1.47	Ilv ⁺	1.0×10^{-5}
$\times 1846$	1.12	—	—
$\times 1849$	0.93	Ilv ⁺	1.5×10^{-5}
$\times 1855$	$<1.3 \times 10^{-4}$	—	—
$\times 1859$	$<1.3 \times 10^{-4}$	Ilv ⁺	7.6×10^{-6}
		Thr ⁺	1.5×10^{-6}
$\times 1864$	$<1.3 \times 10^{-4}$	Thr ⁺	3.0×10^{-6}
$\times 1776$	$<1.3 \times 10^{-10}$	Thr ⁺	2.3×10^{-7}

^aP1L4 ($\times 289$) was used and all strains were grown in L broth + DAP, Thd + 2.5×10^{-3} M CaCl₂, to log phase. Preadsorption was permitted for 30 min at 37°C. prior to plating on L agar by the soft agar method. 2.5×10^{-3} M CaCl₂, DAP and Thd were added to L agar and L soft agar. Plating on $\times 289$ gave 7.5×10^{10} pfu/ml; this was taken as an efficiency of plating of 1.0.

^bRepresentative data from transductions with P1L4 ($\times 289$) P1L4 grown on other $\times 289$ derivatives. P1L4 was added at a multiplicity of about one and preadsorption occurred during a 30 min incubation at 37°C. prior to addition of citrate and direct plating on selective MA.

TABLE 12.
Minimal Inhibitory Concentrations for Various Antibiotics, Mutagens, Drugs,
Detergents and Bile Salts*.

Strain	Number of Cells Spotted	MIC ($\mu\text{g/ml}$)									
		Ap	Cm	Fos	Km	Nal	Rif	Cyc	Sm	Sp	Tc
x289	1.8×10^6	3.1	12.5	200	25	6.25	25	6.25	50	100	6.25
	1.8×10^4	3.1	6.25	100	6.25	3.1	25	3.1	50	100	3.1
	1.4×10^3	3.1	6.25	50	3.1	1.6	6.25	1.6	25	100	1.6
x1841	1.9×10^6	12.5	12.5	800	25	>400	25	50	>400	100	6.25
	1.6×10^4	3.1	6.25	800	12.5	>400	12.5	25	>400	100	3.1
	1.2×10^2	3.1	6.25	400	12.5	>400	12.5	25	>400	50	1.6
x1776	1.0×10^6	3.1	3.1	100	3.1	400	0.8	50	25	50	3.1
	4.9×10^3	3.1	1.6	100	3.1	200	0.4	25	12.5	50	1.6
	5.5×10^1	3.1	0.8	50	3.1	200	0.1	25	6.25	25	0.8
x1925	1.0×10^6	3.1	3.1	100	6.25	>400	6.25	50	50	100	3.1
	1.0×10^4	3.1	1.6	50	6.25	>400	3.1	25	50	50	1.6
x1876	1.3×10^6	3.1	3.1	100	3.1	400	0.8	50	50	50	100
	4.0×10^3	3.1	0.8	100	3.1	200	0.4	25	25	50	50
	4.3×10^1	3.1	0.8	50	3.1	200	0.1	25	6.25	25	50

TABLE 12.
Minimal Inhibitory Concentrations for Various Antibiotics, Mutagens, Drugs,
Detergents and Bile Salts* (continued).

Strain	Number of Cells Spotted	Tp	AO	EB	MC	MMS	MIC ($\mu\text{g/ml}$)			Brij 58	Bile Salts
							SDS	SL	DC		
x ²⁸⁹	1.8×10^6	6.25	>100	>100	25	ND	12800	12800	12800	12800	6000
	1.8×10^4	6.25	>100	>100	6.25	ND	12800	12800	12800	12800	6000
	1.4×10^2	3.1	>100	>100	6.25	ND	12800	12800	12800	12800	6000
x ¹⁸⁴¹	1.9×10^6	6.25	>100	>100	25	1600	12800	12800	12800	12800	6000
	1.6×10^4	6.25	>100	>100	12.5	1600	12800	12800	12800	12800	6000
	1.2×10^2	1.6	>100	>100	12.5	800	12800	12800	12800	12800	6000
x ¹⁷⁷⁶	1.0×10^6	200	>100	>100	6.25	1600	400	100	800	12800	750
	4.9×10^3	200	>100	>100	0.4	1600	200	100	400	12800	370
	5.5×10^1	100	>100	>100	0.2	400	200	50	200	12800	190
x ¹⁹²⁵	1.0×10^6	ND	>100	>100	6.25	ND	12800	12800	12800	12800	12800
	1.0×10^4	ND	>100	>100	0.4	ND	12800	12800	12800	12800	6000
x ¹⁸⁷⁶	1.3×10^6	200	>100	>100	6.25	1600	400	100	800	12800	750
	4.0×10^3	200	>100	>100	0.8	1600	200	100	400	12800	370
	4.3×10^1	200	>100	>100	0.2	400	200	50	200	12800	190

TABLE 13 (continued).

Strain	Total Bacteria fed/rat	Number of rats/strain	Mean titer/rat/0.1 g of feces at designated hours after feeding							
			0	6	12	18 ^b	24	48	72	120
x ¹⁷⁷⁶⁻⁹ ^e	3 × 10 ⁹	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁷⁷⁶⁻¹⁴ ^e	1 × 10 ¹⁰	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁷⁷⁶⁻¹⁸ ^e	3 × 10 ⁹	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁷⁷⁶⁻²³ ^e	1 × 10 ¹⁰	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁷⁷⁶⁻³² ^e	8 × 10 ⁹	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁹²⁹ ^d	1 × 10 ⁹	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁹³⁰ ^d	4 × 10 ⁹	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁹²⁵ ^d	6 × 10 ⁹	3	<4	5 × 10 ³	3 × 10 ³	<4	<4	<4	—	—
x ¹⁹²⁶ ^{d,e}	6 × 10 ⁹	3	<4	<4	<4	—	<4	<4	—	—
x ¹⁸⁷⁶	7 × 10 ⁹	9	<4	<4	<4	<4	<4	<4	—	—
x ¹⁹²⁸ ^{d,e}	1 × 10 ¹⁰	3	<4	<4	2 × 10 ⁴	—	<4	<4	—	—
x ^{1876 + Tc} ^{e,f}	1 × 10 ¹⁰	3	<4	<4	8 × 10 ⁴	—	3 × 10 ²	<4	—	—
x ^{1928 + Tc} ^{e,f}	1 × 10 ¹⁰	3	<4	<4	5 × 10 ⁷	—	5 × 10 ⁴	<4	—	—

TABLE 13 (continued).

*Overnight cultures of the strains were inoculated into an appropriate volume (100 or 500 ml) of L broth + DAP + Thy + Nal (100 μ g/ml, 40 μ g/ml and 25 μ g/ml, respectively) and incubated without aeration in sealed containers at 37°C. Cells were harvested in early stationary phase by centrifugation in a GSA rotor of a Sorvall centrifuge at 7000 rpm for 20 min. The bacteria were suspended in 30 to 40 ml of BSG + DAP + Thy and centrifuged in an SS-34 rotor at 10,000 r.p.m. for 10 min at room temperature. The resulting pellets were suspended in milk + DAP + Thy (Barber's homogenized milk, Birmingham, Ala.) to a final volume of 1.0 ml and titered immediately on L agar + DAP + Thy and on EMB + 1% Mtl + Ade, DAP, Bio, Thy, Pdx (this EMB did not contain yeast extract). Samples of 0.2 to 0.25 ml of the milk suspension containing 3×10^9 to 5×10^{10} cells were orally administered to three weanling rats/strain (Charles River, Wilmington, Mass.) by using a 1.0 ml syringe equipped with a cut-off 24 gauge needle with a soldered ball at the tip to permit easy insertion down the esophagus. All subsequent retests for a given strain used these same rats. All rats were individually housed in suspended cages. Fresh fecal pellets (0.1 to 0.15 g/rat) were collected by gently squeezing the rat and suspended in 4 ml L broth + DAP + Thy + Nal (50 μ g/ml) at 0, 6, 12, 24 and 24 hr intervals thereafter. Samplings at 18 hr were included in selected experiments. The fecal pellets were gently homogenized and suspended by use of a sterile tissue grinder and diluted in serial four-fold dilutions (10^0 , $1/4$, $1/16$, $1/64$) in L broth + DAP + Thy + Nal (50 μ g/ml) and incubated for 48 hr at 37°C. Titers of these serial dilutions were scored on a growth-no growth basis by spotting a loopful of culture on EMB + Mtl agar (plus supplements) and incubating them for 48 hr at 37°C. This method allowed detection of as few as 4 cells/fecal pellet. For higher titers, the original suspension (before incubation) was diluted in 10-fold increments in BSG + DAP + Thy, plated directly onto EMB + Mtl plates (plus supplements) which were incubated at 37°C. for 48 hr. The genotype of the Mtl⁺ strains that were recovered were checked for their ability to grow on MA + Glc with no supplements; L agar + DAP + Thy; L agar + Thy; MA + CAA + DAP + Bio + Thy (40 μ g/ml) + Glc; MA + CAA + DAP + Bio + Thy (2 μ g/ml) + Glc; and MA + CAA + DAP + Bio + Glc.

^bThe 18 hr sample represents only 3 rats/strain.

^cThese derivatives were obtained by picking colonies or papillae from various media on which χ_{1776} had been plated at high density. All isolates had the same genotypic and phenotypic properties as χ_{1776} except some of them plated at higher efficiency than χ_{1776} on media such as MA + CAA, DAP, Thd, Bio; MA + CAA, DAP, Thd, Bio, Glyc; Tryptone agar + DAP, Thd, Bio; etc.

^dSee Table 6 for origin of derivative.

^e χ_{1926} , χ_{1928} , χ_{1876} + Tc, χ_{1928} + Tc were serially diluted in L broth + DAP + Thy + Nal (25 μ g/ml) instead of the usual 50 μ g/ nalidixic acid/ml.

^fThe water of these rats was replaced with 3 mg tetracycline/ml 24 hr before administering the respective strains. At the time of feeding the concentration of tetracycline was reduced to 0.5 mg/ml and maintained throughout the experiment.

UTILITY ASSOCIATED WITH MICROORGANISMS GENETICALLY MODIFIED IN ACCORDANCE WITH THIS INVENTION.

ISOLATION OF MUTANT DERIVATIVES.

5 It is known that *dap* cells surviving DAP-less death in a minimal medium are enriched with respect to mutants that cannot grow in said medium and therefore do not undergo DAP-less death. It is also known that *thyA* cells surviving thymineless death in a minimal medium are enriched with respect to mutants that cannot grow in said medium and therefore do not undergo thymineless death. The standard method for mutant enrichment in *dap*⁺ *thy*⁺ strains utilizes the addition of ampicillin and/or cycloserine to kill non-mutant cells and enrich for mutant cells. The availability of strains such as χ_{1776} , χ_{1972} , χ_{1976} and χ_{2076} that require both diaminopimelic acid and thymidine for growth permits the development of a mutant enrichment procedure that utilizes the combined benefits of DAP-less death, thymineless death and ampicillin + cycloserine enrichment for the isolation of rare mutants from these strains. Such a method has been developed and

10

15

achieves the stated aims. Mutant derivatives of $\times 1776$, $\times 1972$, $\times 1976$ and $\times 2076$ should be very useful for many studies with recombinant DNA molecules and this mutant enrichment technique will therefore have broad utility.

ISOLATION OF PLASMID VECTOR DNA.

Since $\times 1776$, $\times 1972$, $\times 1976$ and $\times 2076$ are very sensitive to ionic detergents, it is essential for success in transforming such strains that any and all DNA preparations used for transformation be free from such ionic detergents. Since these strains are as resistant to non-ionic detergents such as Brij-58 (Trademark), or Triton-X100 (Trademark) as are wild-type strains of *E. coli*, it is advisable to use these non-ionic detergents or a polyoxyethylene ether of a higher aliphatic alcohol rather than ionic detergents for the isolation of plasmid cloning vector DNA whether containing or not containing foreign DNA for the introduction into these strains by transformation. Methods of cloning vector DNA isolation that do not require use of detergents are even more preferable.

Methods for isolation of plasmid cloning vector DNA have therefore been developed which are based on modifications of the standard methods for preparation of cleared lysates (Guerry et al., 1973) and for ethidium bromide-CsCl centrifugation purification of plasmid DNA (Mukai et al., 1973). These modifications are as follows:

1. When the host strain containing the plasmid cloning vector is a "wild-type-like" host such as W1485, C600, etc., the final concentrations of sodium dodecyl sulfate or Sarkosyl used to lyse the lysozyme-generated spheroplasts should be reduced from the usual 1 to 5% to 0.25%. Other methods are as described by Guerry et al. and Mukai et al. except that after removal of ethidium bromide by isopropanol extraction the purified plasmid cloning vector DNA is dialyzed at 4°C against 500 ml of TEN buffer (Tris, 20 mM; EDTA, 2 mM; NaCl, 10 mM; pH 8.0), the buffer being changed every 12 hours over a period of 3 to 4 days to remove all CsCl and residual detergent. This DNA is then stored in TEN buffer at 4°C and diluted into Tris (0.02 M) — NaCl (0.8%) buffer (pH 8.0) for use in transformation. The use of non-ionic detergents for these "wild-type-like" hosts does not give satisfactory yields of plasmid DNA.

2. When the host strain containing the plasmid cloning vector is $\times 1776$ or another similarly modified host, the final concentration of sodium dodecyl sulfate or Sarkosyl can be reduced to 0.1% for the lysis of lysozyme-generated spheroplasts. Other procedures are as in 1. above.

3. When the host strain containing the plasmid cloning vector is $\times 1776$ or another similarly modified host, the lysozyme-generated spheroplasts can be lysed by the addition of Brij-58 or another non-ionic detergent to a final concentration of 0.25%. The DNA should be dialyzed at 4°C as described in 1. above but only needs to be dialysed for a period of 24 to 36 hours.

4. When the host strain containing the plasmid cloning vector is $\times 1776$ or another similarly modified host, the lysozyme-generated spheroplasts can be lysed by an osmotic temperature shock by the addition of an equal volume of ice-cold water adjusted to pH 9. Dialysis of DNA can be as in 3 above.

PROCEDURE FOR TRANSFORMATION OF $\times 1776$.

Due to the nature of the cell surface in $\times 1776$ and in another genetically modified microorganisms, existing methods of transformation with plasmid vector DNA give very low yields of transformants. This difficulty can be further intensified depending on the method of plasmid DNA isolation and the extent of dialysis of such DNA as indicated hereinabove. It has therefore been desirable to develop a new procedure for the optimal transformation of $\times 1776$. An enumeration of the steps in this procedure follows:

1. Prepare an overnight culture (18 hours) of $\times 1776$ by growing in 5 ml of L broth + DAP (100 $\mu\text{g/ml}$) + Thd (5 $\mu\text{g/ml}$) at 37°C. as a standing culture.

2. Dilute the overnight culture 1:10 into 20 ml of L broth + DAP + Thd and incubate at 37°C. with aeration (e.g., shaking) for 3 to 4 hours until the culture reaches an optical density of 0.5 to 0.6 at A_{600} .

3. Sediment the cells in the culture by centrifugation at 4°C. for 10 minutes at $8700 \times g$ (e.g., at 8500 rpm in SS-34 rotor of Sorvall Refrigerated Centrifuge).

4. Discard the supernatant culture medium and gently resuspend the pellet in 10 ml ice-cold 10 mM NaCl.

5. Sediment the cells as in 3 above.

6. Discard the supernatant fluid and *gently* resuspend the pellet in 10 ml ice-cold 75 mM CaCl_2 in Tris-HCl (10 mM) buffer (pH 8.4) and place in an ice bucket for 20 to 25 minutes. (Note: The pH of the CaCl_2 solution is critical and the pH of CaCl_2 solutions has been found to depend on whether anhydrous CaCl_2 or $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ is used, the "age" of the opened CaCl_2 bottle and the quality of the suspending water. Solutions at pH 8.4 give the optimal yields of transformants.)

7. Sediment the cells as in 3 above.

8. Discard the supernatant fluid and *gently* resuspend the pellet in 2.0 ml of ice-cold 75 mM CaCl_2 in Tris-HCl (10 mM) buffer (pH 8.4) and place in ice bucket.

9. Add 100 μl of plasmid vector and/or recombinant DNA in 0.02M Tris, 0.8% NaCl (pH 8.0) to a clean Pyrex (Trademark) test tube in an ice bucket at 0°C . The DNA should be at a concentration of about 0.2 $\mu\text{g}/\text{ml}$.

10. Then add 200 μl of chilled cells from 8 above. These should be at a concentration of 0.9 to 2.0×10^9 colony forming units/ml although lower concentrations of cells (e.g., $2.0 \times 10^9/\text{ml}$) give somewhat higher absolute efficiencies of transformation.

11. Keep the tube at ice temperature for 20 to 25 minutes.

12. Then rapidly heat the tube to 42°C . in a water bath and maintain it at that temperature for one minute. Longer incubations at 42°C . have little or no effect in further increasing transformant yield.

13. Then chill the tube in ice bucket for 10 minutes.

14. If the cloning vector is pSC101, pMB9 or a derivative thereof, plate 0.1 ml samples directly on EMB + DAP + Thd + 1% Glucose + 25 μg nalidixic acid/ml + 12.5 μg tetracycline/ml. If plating by spreading, distribute the sample over the surface of the plates and allow fluid to dry into the plate. Spreading to dryness reduces transformant yield. The plating medium should be prepared the same day (or one day before) and should not be dried at 42°C . or above since tetracycline is converted to a toxic product.

15. If the cloning vector is pCR1 or a derivative thereof, take 0.1 ml of the transformant mixture and add to 0.9 ml L broth + DAP + Thd + 25 μg nalidixic acid/ml and incubate at 37°C . for 2 hours before plating on EMB + DAP + Thd + 1% Glucose + 25 μg nalidixic acid/ml + 25 μg kanamycin/ml.

16. Incubate the plates for 2 to 3 days at 37°C .
Note: All glassware, centrifuge tubes, etc. should be clean and free from scratches that could accumulate residual detergent used in cleaning.

SPECIFIC USES OF GENETICALLY MODIFIED MICROORGANISMS FOR WORK WITH RECOMBINANT DNA MOLECULES.

$\times 1776$ (Chart C) — compatible for use with non-conjugative plasmid cloning vectors such as pSC101, pMB9, pCR1, etc.

$\times 2076$ (Chart D) — compatible for use with non-conjugative plasmid cloning vectors such as pSC101, pMB9, pCR1, etc.

$\times 1963$ (Chart E) — compatible for use with λ -derived cloning vectors that are unable to lysogenize host and are dependent on presence of amber suppressor mutations in host for their replication and maturation with production of infectious phage particles.

$\times 1961$ (Chart E) — Useful for testing λ vectors compatible with $\times 1963$ for retention of amber suppressible mutations in vector and compatible for use with λ vectors that are unable to lysogenize host and possess amber suppressible mutations that prevent production of phage tails and/or assembly of phage tails to phage heads but which do not prevent phage vector replication or assembly of phage vector heads containing DNA.

$\times 1972$ (Chart E) — Compatible for use with λ vectors that can lysogenize host and whose maturation and assembly into infectious phage particles is dependent on presence of amber suppressible mutations in host. Is also compatible for use with non-conjugative plasmid cloning vectors whose maintenance, replication and function is independent of presence of amber suppressor mutations in host.

$\times 1976$ (Chart E) — Compatible for use with non-conjugative plasmid cloning vectors such as pSC101, pMB9, pCR1 and derivatives thereof and with plasmid cloning vectors derived from λ such as λdv and derivatives thereof.

^x1966, ^x1968, ^x1969, ^x1970, ^x1973, ^x1974 and ^x1975 (Chart E) — These modified hosts are likely to be compatible for use with certain viral and plasmid cloning vectors that have not yet been developed.

A deposit of the *Escherichia coli* K-12 ^x1776 has been placed with the American Type Culture Collection, Rockville, Maryland, U.S.A. and has been assigned ATCC No. 31244.

Although emphasis has been placed in this disclosure on the preparation of highly specialized microorganisms derived from *E. coli*, microorganisms in accordance with the practices of this invention are capable of being modified and/or prepared from other bacteria or microorganisms or cells, including eucaryotic microorganisms or cells and procaryotic microorganisms or cells. Yeasts, molds, algae, *Protozoa* and other microorganisms or cellular material are capable of modification and/or genetic alteration in accordance with the practices of this invention to be useful as hosts for cloning recombinant DNA molecules and capable of reproduction and/or possessing other useful physical and/or biochemical or genetic properties. Other such microorganisms include the *Bacillus* bacteria, e.g. *B. subtilis* and variants thereof, *B. licheniformis*, *B. stearothermophilus*; the *Pseudomonas*, e.g. *P. fluorescens*, *P. putrefaciens*, or *P. putida* or variants thereof; the *Streptomyces*, such as *S. aureofaciens*, and *S. coelicolor* or variants thereof; the *Rhizobiums*, such as species thereof which form root nodules on plants, e.g. legumes, particularly those which fix nitrogen involving a symbiotic relationship between the *Rhizobium* bacteria and a plant. Other microorganisms usefully altered in accordance with the practices of this invention include the yeasts, such as the *Saccharomyces*, e.g. *S. cerevisiae*.

In general, as indicated hereinabove, any microorganism or cellular material, particularly a procaryotic microorganism, is capable of alteration in accordance with the practices of this invention to yield a microorganism having the desired characteristics in accordance with this invention.

Following is a listing of the literature or publications cited hereinabove as being of interest in connection with various aspects of the practices of this invention.

LITERATURE CITED.

1. Adams, M. H. 1959. *Bacteriophages*. New York: Interscience Publishers, p. 592.
2. Bachmann, B. J. 1972. *Bacteriol. Rev.* 36:525—557.
3. Bachmann, B. J., Low, K. B. and Taylor, A. L. 1976. *Bacteriol. Rev.* 40:116—167.
4. Berg, C. M. and Curtiss, R., III 1967. *Genetics* 56:503—525.
5. Bukhari, A. I. and Taylor, A. L. 1971. *J. Bacteriol.* 105:844—854.
6. Curtiss, R., III. 1964. *Genetics* 50:679—694.
7. Curtiss, R., III. 1965. *J. Bacteriol.* 89:28—40.
8. Curtiss, R., III, Charamella, L. J., Stallions, D. R. and Mays, J. A. 1968. *Bacteriol. Rev.* 32:320—348.
9. Curtiss, R., III, Macrina, F. L. and Falkinham, J. O., III. 1974. *Escherichia coli* — An overview. In: *Handbook Of Genetics*. Vol. I. R. C. King (ed.). pp. 115—133 (New York).
10. Demerec, M., Adelberg, E. A., Clark, A. J. and Hartman, P. E. 1966. *Genetics* 54:61—76.
11. Frazer, A. C. and Curtiss, R., III. 1975. *Curr. Topics Microbiol. Immunol.* 69:1—84.
12. Gross, J. D. and Caro, L. G. 1966. *J. Mol. Biol.* 16:269—284.
13. Guerry, P., LeBlanc, D. J. and Falkow, S. 1973. *J. Bacteriol.* 116:1064—1066.
14. Kellenberger, G., Symonds, N. and Arber, W. 1966. *Z. Vererbungsl.* 98:247—256.
15. Lennox, E. S. 1955. *Virology* 1:190—206.
16. Miller, J. H. 1972. *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory, New York.
17. Mukai, T., Matsubara, K. and Takagi, Y. 1973. *Proc. Nat. Acad. Sci. U.S.A.* 70:2884—2887.
18. Reiner, A. M. 1969. *J. Bacteriol.* 97:1431—1436.
19. Stallions, D. R. and Curtiss, R., III. 1971. *J. Bacteriol.* 105:886—895.
20. Wood, W. B. 1966. *J. Mol. Biol.* 16:118—133.

Although emphasis in the practices of this invention has been placed on the alteration and/or development of a special microorganism derived from *E. coli*, the practice of this invention in its various embodiments is generally applicable, as indicated hereinabove, to numerous types of microorganisms or cellular material, such as eucaryotic and procaryotic microorganisms, Gram-positive and Gram-negative microorganisms, yeasts, and other microorganisms. The practices of this invention are also applicable to the alteration, development and/or production of a microorganism useful for the insertion of a recombinant DNA molecule or recombinant DNA therein, the resulting recombinant DNA-containing microorganism or cellular material being capable of growth and replication with the ultimate expression of the characteristics of the recombinant DNA incorporated therein, e.g. in the instance wherein the recombinant DNA controls and/or expresses itself by the production of insulin or a human hormone or other bio-affecting material, there should be produced upon growth or culturing of the recombinant DNA-containing microorganism insulin, human hormone or bio-affecting material.

WHAT WE CLAIM IS:—

1. A microorganism having the following characteristics:

(a) said microorganism being capable of having recombinant DNA or other foreign genetic information introduced therinto and recovered therefrom along with its expression with production of useful gene products;

(b) said microorganism being dependent for growth and survival upon defined conditions;

(c) said microorganism being incapable of establishment or growth or colonization and/or survival under conditions or in ecological niches that are non-permissive for said microorganism;

(d) said microorganism being capable of causing DNA or other foreign genetic information incorporated therein to undergo degradation under conditions or in ecological niches that are non-permissive for said microorganism;

(e) said microorganism being capable of permitting cloning vectors incorporated therein to be dependent for their replication, maintenance and/or function on said microorganism;

(f) said microorganism being substantially incapable of transmitting cloning vectors or recombinant DNA or other foreign genetic information incorporated therein to other organisms under non-permissive conditions for said microorganism;

(g) said microorganism being capable of being monitored by suitable means and/or techniques without substantial alteration of said microorganism; and

(h) said microorganism being susceptible of substantially minimal contamination with other organisms when recombinant DNA or other foreign genetic information is incorporated therein and being substantially incapable of contaminating other organisms when incorporated therein or consumed thereby when recombinant DNA or other foreign genetic information is present in said microorganism.

2. A microorganism in accordance with claim 1 which is incapable of survival in the absence of diaminopimelic acid.

3. A microorganism in accordance with claim 1 which is incapable of survival in the absence of thymine.

4. A microorganism in accordance with claim 1 which is incapable of survival in the presence of bile salts.

5. A microorganism in accordance with claim 1 which exhibits resistance to nalidixic acid.

6. A microorganism in accordance with claim 1 which exhibits resistance to cycloserine.

7. A microorganism in accordance with claim 1 which exhibits resistance to trimethoprim.

8. A microorganism in accordance with claim 1 which exhibits sensitivity to ionic detergents.

9. A microorganism in accordance with claim 1 wherein the microorganism is a strain of *Escherichia coli*.

10. A microorganism in accordance with claim 1 wherein the microorganism is obtained from a *Bacillus* microorganism.

11. A microorganism in accordance with claim 3 wherein the *Bacillus* microorganism is *B. subtilis* or a variant thereof.

12. A microorganism in accordance with claim 1 wherein the microorganism is obtained from a *Pseudomonas* microorganism.
13. A microorganism in accordance with claim 12 wherein the *Pseudomonas* is *P. putida* or a variant thereof.
14. A microorganism in accordance with claim 1 wherein the microorganism is obtained from a *Streptomyces* microorganism.
15. A microorganism in accordance with claim 1 wherein the *Streptomyces* microorganism is *S. aureofaciens* or a variant thereof.
16. A microorganism in accordance with claim 1 wherein the microorganism is obtained from a *Rhizobium* microorganism.
17. A microorganism in accordance with claim 1 wherein the microorganism is obtained from a yeast.
18. A microorganism in accordance with claim 17 wherein the yeast is a *Saccharomyces* microorganism.
19. A microorganism in accordance with claim 1 wherein the microorganism is obtained from an *Escherichia* microorganism.
20. A microorganism derived from the microorganism PA 678 Str⁺ Azi⁺ selected from the derivative microorganisms listed in Chart A herein.
21. A microorganism derived from the microorganism x1276 selected from the derivative microorganisms listed in Chart C herein.
22. A microorganism derived from the microorganism x1776 selected from the derivative microorganisms listed in Chart D herein.
23. A microorganism derived from the microorganism x1038 selected from the derivative microorganisms listed in Chart E herein.
24. *Escherichia coli* K-12 x1776.
25. *Escherichia coli* K-12 x1972.
26. *Escherichia coli* K-12 x1976.
27. *Escherichia coli* K-12 x1961.
28. *Escherichia coli* K-12 x1963.
29. *Escherichia coli* K-12 x1966.
30. *Escherichia coli* K-12 x1968.
31. *Escherichia coli* K-12 x1969.
32. *Escherichia coli* K-12 x1970.
33. *Escherichia coli* K-12 x1973.
34. *Escherichia coli* K-12 x1974.
35. *Escherichia coli* K-12 x1975.
36. *Escherichia coli* K-12 x2076.
37. *Escherichia coli* K-12 x1876.
38. A microorganism in accordance with Claim 1 wherein said microorganism is a Gram-negative microorganism.
39. A microorganism in accordance with Claim 1 wherein said microorganism is a Gram-positive microorganism.
40. A microorganism in accordance with Claim 1 wherein said microorganism is a procaryotic microorganism.
41. A microorganism in accordance with Claim 1 wherein said microorganism is a eucaryotic microorganism.
42. A method for improving the introduction of foreign genetic information into a host microorganism which comprises utilizing as the host a mutant microorganism containing mutation (3) and/or (4) listed under a1 of Mutation Chart A herein.
43. A method for improving the recovery of foreign genetic information provided or incorporated within a microorganism which comprises utilizing all or some of the mutations listed under a2 of Mutation Chart A herein.
44. A method for producing a microorganism to be dependent on defined conditions for growth and/or survival which comprises incorporating into the microorganism all or some of the mutations listed under b of Mutation Chart A herein.
45. A method for producing a microorganism to preclude the establishment or growth or colonization and/or survival of the microorganism under conditions or in ecological niches that are non-permissive for the microorganism or its progenitors which comprises incorporating into the microorganism all or some of the mutations listed under c of Mutation Chart A herein.
46. A method for producing a microorganism so as to cause genetic information contained within said microorganism to undergo degradation under conditions or in ecological niches that are non-permissive for the microorganism

or its progenitors which comprises incorporating into the microorganism all or some of the mutations listed under d of Mutation Chart A herein.

47. A method of precluding or minimizing or reducing the potential or capability of a microorganism to transmit recombinant DNA incorporated therein to another organism or microorganism which comprises incorporating into the microorganism all or some of the mutations listed under f of Mutation Chart A herein.

48. A method of monitoring a microorganism which comprises incorporating into the microorganism all or some of the mutations listed under g and h of Mutation Chart A herein.

49. A method in accordance with claim 48 wherein recombinant DNA is subsequently incorporated into the microorganism.

50. A method for the transformation of a strain of *E. coli* for the introduction of recombinant DNA molecules therein comprising

(a) preparing an overnight culture of said strain in L broth + DAP + Thd at a temperature of about 37°C.;

(b) diluting 1:10 into 20 ml. LB + DAP + Thd;

(c) centrifuging at 4°C. for 10 minutes at 8700 × g;

(d) resuspending the resulting pellet in 10 ml. ice-cold 10 mM NaCl;

(e) centrifuging at 4°C. for 10 minutes at 8700 × g;

(f) resuspending the pellet in 10 ml. ice-cold 75 mM CaCl₂ (pH 8.4) and placing it in an ice bucket for about 20—25 minutes;

(g) centrifuging at 4°C. for 10 minutes as step (c) above;

(h) resuspending the pellet in 2.0 ml. ice-cold 75 mM CaCl₂ (pH 8.4);

(i) adding 100 μl plasmid DNA in 0.2 M Tris, 0.8% NaCl, pH 8.0 to a clean test tube in an ice bucket, the DNA being at a concentration of about 0.2 μg/ml., then adding 200 μl of cells from (h) above at 0.9 – 2.0 × 10⁹ colony forming units/ml.;

(j) maintaining the test tube at ice temperature for about 20—25 minutes;

(k) heating to 42°C. in a water bath for one minute;

(l) chilling the test tube in an ice bucket for 10 minutes;

(m) plating the resulting transformation mixture; and

(n) incubating the plates 2—3 days at 37°C.

51. A method for the transformation of a strain of *E. coli* for the introduction of recombinant DNA molecules therein comprising

(a) preparing an overnight culture of said strain in L broth + DAP + Thd at a temperature of about 37°C.;

(b) diluting 1:10 into 20 ml. LB + DAP + Thd;

(c) centrifuging at 4°C. for 10 minutes at 8,700 × g;

(d) resuspending the resulting pellet in 10 ml. ice-cold 10 mM NaCl;

(e) centrifuging at 4°C. for 10 minutes at 8700 × g;

(f) resuspending the pellet in 10 ml. ice-cold 75 mM CaCl₂ (pH 8.4) and placing it in an ice-bucket for about 20—25 minutes;

(g) centrifuging at 4°C. for 10 minutes as in step (c) above;

(h) resuspending the pellet in 2.0 ml. ice-cold 75 mM CaCl₂ (pH 8.4);

(i) adding 100 μl plasmid DNA in 0.02 M Tris, 0.8% NaCl, pH 8.0 to a clean test tube in an ice bucket, the DNA being at a concentration of about 0.2 μg/ml., then adding 200 μl of cells at 0.9 – 2.0 × 10⁹ colony forming units/ml.;

(j) maintaining the test tube at ice temperature for about 20—25 minutes;

(k) heating to 42°C. in a water bath for one minute;

(l) chilling the test tube in an ice bucket for 10 minutes;

(m) when using pSC101 or pMB9, plate 0.1 ml. samples on EMB + 1% Glucose + DAP + Thd + 25 μg Nalidixic acid/ml. + 12.5 μg Tetracycline/ml., the plates having been prepared one day before or same day, and when using pCR1, taking 0.1 ml. of transformant mixture and adding to 0.9 ml. LB + DAP + Thd + 25 μg Nal/ml. and incubating for 2 hours at 37°C. before plating on the EMB agar with 25 μg kanamycin/ml. (without tetracycline); and

(n) incubating the plates 2—3 days at 37°C.

52. A method for transforming a microorganism according to any of claims 1 to 41 with plasmid vector DNA which includes the steps of subjecting the microorganism to a cold osmotic pressure shock treatment by suspension in a chilled salt solution, admixing the chilled microorganism with the DNA and subjecting the mixture to a hot shock treatment by rapidly raising the temperature to above ambient temperature.

53. A method in which recombinant DNA is introduced into a microorganism suitable for replication therein or for the production of material from said

microorganism dependent on said recombinant DNA upon growth or culturing of said microorganism, wherein there is employed as said microorganism a microorganism in accordance with any of claims 1 to 8.

5 54. A method in which recombinant DNA is introduced into a microorganism suitable for replication therein or for the production of material from said microorganism dependent on said recombinant DNA upon growth or culturing of said microorganism, wherein there is employed as said microorganism *Escherichia coli* K—12 \times 1776. 5

10 55. A method in which recombinant DNA is introduced into a microorganism suitable for replication therein or for the production of material from said microorganism dependent on said recombinant DNA upon growth or culturing of said microorganism, wherein there is employed as said microorganism *Escherichia coli* K—12 \times 1976. 10

15 56. A method in which recombinant DNA is introduced into a microorganism suitable for replication therein or for the production of material from said microorganism dependent on said recombinant DNA upon growth or culturing of said microorganism, wherein there is employed as said microorganism *Escherichia coli* K—12 \times 2076. 15

20 57. A method as claimed in claim 53 wherein the said material is bio-affecting material. 20

58. A method as claimed in claim 53 wherein the said material is insulin or human hormone material.

59. A method as claimed in any of claims 54 to 56 wherein the said material is bio-affecting material.

25 60. A method as claimed in any of claims 54 to 56 wherein the said material is insulin or human hormone material. 25

61. A method for the production of a microorganism as claimed in any one of claims 1 to 41, substantially as described herein with reference to the relevant Genealogy Chart.

R. G. C. JENKINS & CO.,
Chartered Patent Agents,
Chancery House,
53/64 Chancery Lane,
London WC2A 1QU.
Agents for the Applicants.